STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 134481

TO: Zohreh Fay **Location: 3a61 / 3c70** **Wednesday, October 13, 2004** **Art Unit: 1614** **Phone: 272-0573** **Serial Number: 10 / 644870**	**From: Jan Delaval** **Location: Biotech-Chem Library** **Rem 1A51** **Phone: 272-2504** **jan.delaval@uspto.gov**

Search Notes

Access DB# 134481

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Zelda Fay Examiner #: 66646 Date: 10/5/04
Art Unit: 1614 Phone Number 305-243-2273 Serial Number: 10/644,870
Mail Box and Bldg/Room Location: 3C70 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. MEJ

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Eye drop Composition

Inventors (please provide full names): Ueno, Ryuji

Earliest Priority Filing Date: 8/21/02

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search the composition and method of use.

Jan

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: Jan	NA Sequence (#)	STN ✓
Searcher Phone #: 22504	AA Sequence (#)	Dialog
Searcher Location:	Structure (#) ✓	Questel/Orbit
Date Searcher Picked Up: 10/13	Bibliographic	Dr.Link
Date Completed: 10/13	Litigation	Lexis/Nexis
Searcher Prep & Review Time:	Fulltext	Sequence Systems
Clerical Prep Time: 15	Patent Family	WWW/Internet
Online Time: +20	Other	Other (specify)

PTO-1590 (8-01)

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 10:32:37 ON 13 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 OCT 2004  HIGHEST RN 760932-70-5
DICTIONARY FILE UPDATES:  11 OCT 2004  HIGHEST RN 760932-70-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d sta que l9
L6              STR
```




```
VAR G1=C/9
VAR G2=O/X/AK/13
VAR G3=C/23/20
VAR G4=OH/X/AK/25/13
NODE ATTRIBUTES:
NSPEC    IS RC     AT  27
CONNECT IS M1  RC AT  27
CONNECT IS M1  RC AT  28
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS  23

STEREO ATTRIBUTES: NONE
L9        34244 SEA FILE=REGISTRY SSS FUL L6

100.0% PROCESSED 388231 ITERATIONS                    34244 ANSWERS
SEARCH TIME: 00.00.11
```

=> d l12 ide can tot

L12 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN
RN **607351-44-0** REGISTRY
CN 5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-N-ethyl-, (5Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H39 N O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:344877

REFERENCE 2: 139:296971

L12 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN
RN **369585-22-8** REGISTRY
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxo-5-phenylpentyl)cyclopentyl]-, (5Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H32 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:212793

REFERENCE 2: 140:344877

REFERENCE 3: 136:299713

REFERENCE 4: 136:178021

REFERENCE 5: 135:327373

L12 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN
RN **163075-10-3** REGISTRY
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]butyl]cyclopentyl]-, 1-methylethyl ester, (5Z)-(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5-Heptenoic acid, 7-[3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]butyl]cyclopentyl]-, 1-methylethyl ester, [1R-[1α(Z),2β(R*),3α,5α]]-
OTHER NAMES:
CN 13,14-Dihydrofluprostenol isopropyl ester
FS STEREOSEARCH
MF C26 H37 F3 O6
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:344877

REFERENCE 2: 138:368671

REFERENCE 3: 134:162867

REFERENCE 4: 122:290579

L12 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN
RN **130209-82-4** REGISTRY
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5-Heptenoic acid, 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl]-, 1-methylethyl ester, [1R-[1α(Z),2β(R*),3α,5α]]-
OTHER NAMES:
CN 5: PN: WO03079997 PAGE: 17 claimed sequence
CN Latanoprost
CN PhXA 41
CN XA 41
CN Xalatan
FS STEREOSEARCH
DR 144489-49-6
MF C26 H40 O5
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

325 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
327 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:254451

REFERENCE 2: 141:230312

REFERENCE 3: 141:218906

REFERENCE 4: 141:185135

REFERENCE 5: 141:179214

REFERENCE 6: 141:179203

REFERENCE 7: 141:167661

REFERENCE 8: 141:150902

REFERENCE 9: 141:134031

REFERENCE 10: 141:134030

L12 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN
RN **120373-36-6** REGISTRY
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, (5Z)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5-Heptenoic acid, 7-[3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, [1R-[1α(Z),2β,3α,5α]]-
OTHER NAMES:
CN Unoprostone
FS STEREOSEARCH
MF C22 H38 O5
CI COM
SR CA
LC STN Files: ADISNEWS, BIOBUSINESS, BIOSIS, CA, CAPLUS, CHEMCATS, CIN, CSCHEM, DIOGENES, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PROMT, PROUSDDR, PS, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT

(Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); USES (Uses)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

67 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
67 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:185135

REFERENCE 2: 141:134031

REFERENCE 3: 141:17495

REFERENCE 4: 141:7107

REFERENCE 5: 140:417845

REFERENCE 6: 140:391155

REFERENCE 7: 140:391154

REFERENCE 8: 140:344877

REFERENCE 9: 140:280509

REFERENCE 10: 140:264877

L12 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2004 ACS on STN
RN **120373-24-2** REGISTRY
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5-Heptenoic acid, 7-[3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 1-methylethyl ester, [1R-[1α(Z),2β,3α,5α]]-
OTHER NAMES:
CN 13,14-Dihydro-15-keto-20-ethyl-PGF2
CN Isopropyl unoprostone
CN Rescula
CN UF 021

CN Unoprostone isopropyl ester
FS STEREOSEARCH
MF C25 H44 O5
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CIN, CSCHEM, DIOGENES, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); USES (Uses)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

121 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
121 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:117076

REFERENCE 2: 141:47249

REFERENCE 3: 141:7107

REFERENCE 4: 140:391155

REFERENCE 5: 140:391154

REFERENCE 6: 140:344877

REFERENCE 7: 140:264877

REFERENCE 8: 140:253553

REFERENCE 9: 140:228482

REFERENCE 10: 140:223330

=> d his

```
     (FILE 'HOME' ENTERED AT 09:16:06 ON 13 OCT 2004)
               SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 09:16:15 ON 13 OCT 2004
L1             1 S US20040076678/PN OR (US2003-644870# OR US2002-404779#)/AP,PRN
               E UENO R/AU
L2           207 S E3,E23
               E SUCAMPO/PA,CS
L3            23 S E3-E22
               SEL RN L1

     FILE 'REGISTRY' ENTERED AT 09:18:56 ON 13 OCT 2004
L4            11 S E1-E11
L5             6 S L4 AND C5/ES
L6               STR
L7             0 S L6 CSS
L8            50 S L6 SAM
L9         34244 S L6 FUL
               SAV TEMP L9 FAY644/A
L10              STR L6
L11            0 S L10 CSS SAM SUB=L9
L12            6 S L4 AND L9
L13            1 S 9002-89-5
L14            1 S 56-81-5
L15            1 S 9004-34-6
L16         6694 S 9004-34-6/CRN
L17         1391 S ?CELLULOS?/CNS NOT L16
L18          806 S L17 NOT SQL/FA
L19            2 S (ACRYLIC ACID OR METHACRYLIC ACID)/CN
               SEL RN
L20        91653 S E12-E13/CRN
L21        88521 S L20 AND (C4H6O2 OR C3H4O2)
L22           21 S L21 AND 1/NC NOT IDS/CI
L23            9 S L22 NOT HOMOPOLYMER
L24           12 S L22 NOT L23
L25            7 S L24 NOT (CYCLODEXTRIN OR N/ELS OR OC4/ES)
L26            6 S L25 NOT C10H22O7
L27            1 S 9005-65-6
               E SORBITAN
L28          756 S E3
L29          433 S L28 AND ETHANEDIYL
L30          323 S L28 NOT L29
L31          169 S L30 AND 1/NC
L32           10 S L31 NOT (IDS/CI OR COMPD OR WITH)
L33            1 S L32 AND OXYMETHYLENE
L34          182 S L29 AND 1/NC NOT (IDS/CI OR COMPD OR WITH)
               E POLYSORBATE
L35           21 S E3
L36            9 S L35 AND 1/NC NOT (MXS/CI OR C6/ES OR NC4/ES)
L37        33594 S L9 NOT ((MXS OR PMS OR IDS)/CI OR COMPD OR WITH OR UNSPECIFIE
L38        33263 S L37 AND 1/NC
L39          331 S L37 NOT L38
L40        33257 S L38 NOT L12

     FILE 'HCAPLUS' ENTERED AT 09:50:09 ON 13 OCT 2004
L41          419 S L12
L42          418 S LATANOPROST OR PHXA41 OR PH()(XA41 OR XA 41) OR XA41 OR XA 41
L43           39 S ISOPROPYLUNOPROSTONE OR ISOPROPYL UNOPROSTONE
L44          409 S L39
L45        49180 S L40
               E PROSTAGLANDIN/CT
```

```
L46          17 S E3
L47       39277 S E4,E5,E7,E10,E13,E16,E17,E28,E30,E31,E33,E36,E39
L48       31687 S E63
L49        5095 S E64-E67,E69,E70
                E E63+ALL
L50       68728 S E4,E3+NT
L51       74694 S L41-L50
                E ACRYLIC POLYMER/CT
                E E3+ALL
L52       47858 S E2
                E E2+ALL
L53          40 S L51 AND L52
L54          80 S L51 AND L19,L26
L55          77 S L51 AND L13
L56         167 S L51 AND L14
L57         104 S L51 AND L15
L58         227 S L51 AND L16
L59         201 S L51 AND L18
                E POLYLACTAM/CT
                E E4+ALL
L60           1 S L51 AND E2
                E LACTAM/CT
L61           0 S L51 AND E32
L62          29 S L51 AND E22
L63          24 S L51 AND E23-E31,E34
L64          81 S L51 AND L27,L33,L34,L36
L65          41 S L64 AND L53-L60,L62,L63
L66         599 S L53-L64
L67           3 S L66 AND L1-L3
L68          23 S L66 AND VISCOSITY
L69          32 S L66 AND VISCO?
L70          32 S L68,L69
L71           1 S L67 AND L70
L72          81 S L66 AND L27,L33,L34,L36
L73         110 S L70,L72
                E EYE/CW
L74       74378 S E3,E7,E9,E11,E12
L75       79161 S EYE+OLD,NT,PFT,RT/CT
L76       89281 S EYE, DISEASE+OLD,NT,PFT,RT/CT
                E EYE+ALL/CT
L77       75310 S E8,E7+NT
L78       12626 S E26+OLD,NT
L79        1870 S E27+OLD,NT
L80        4225 S E28+OLD,NT
                E E25+ALL
L81       32125 S E8,E9,E7+NT
L82          28 S L73 AND L74-L81
L83          30 S L73 AND (EYE? OR ?OCULAR? OR ?OPHTHALM?)
L84          41 S L67,L71,L82,L83
L85          69 S L73 NOT L84
                SEL DN AN 31 39
L86           2 S E1-E6 AND L85
L87          12 S L84 AND EYE?/CW
L88          10 S L84 AND (EYE? OR OCULAR? OR OPHTHALM?)/TI
L89           1 S L84 AND OPTHALM?/TI
L90          20 S L87-L89
L91          21 S L84 NOT L90
L92           2 S L91 AND GLAUCOM?
L93          19 S L91 NOT L92
L94           6 S L93 AND OPHTHALMIC
L95          30 S L86,L67,L71,L90,L92,L94
L96          13 S L84 NOT L95
L97           1 S L96 AND EYE NOT IRRITATION TEST
```

```
L98          31 S L95,L97
L99          29 S L98 AND (PD<=20020821 OR PRD<=20020821 OR AD<=20020821)
L100          2 S L98 NOT L99
L101         31 S L98-L100
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 10:25:44 ON 13 OCT 2004
L102         55 S E7-E61
L103         22 S L102 AND L9
L104         33 S L102 NOT L103
L105         28 S L104 AND L13-L16,L19,L26,L27,L33,L34,L36
L106          5 S L104 NOT L105
L107         21 S L103 NOT C20H38O2

     FILE 'HCAPLUS' ENTERED AT 10:29:28 ON 13 OCT 2004
L108      38248 S L107
L109        226 S L105 AND L108
L110         19 S L101 AND L109
L111          3 S L106 AND L101
L112          1 S L111 AND VISCOUS OPHTHALMIC PHARMACEUTICAL
L113         20 S L110,L112
L114         11 S L101 NOT L111,L113
L115          2 S L111 NOT L112
L116         29 S L113,L114 NOT L115

     FILE 'REGISTRY' ENTERED AT 10:32:37 ON 13 OCT 2004

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:32:54 ON 13 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 13 Oct 2004  VOL 141 ISS 16
FILE LAST UPDATED: 12 Oct 2004  (20041012/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> d l116 all hitstr tot

L116 ANSWER 1 OF 29  HCAPLUS  COPYRIGHT 2004 ACS on STN
AN   2004:354690  HCAPLUS
DN   140:315111
ED   Entered STN:  30 Apr 2004
TI   Method using latanoprost for the treatment of ocular
     hypertension and glaucoma
IN   Ueno, Ryuji
PA   USA
SO   U.S. Pat. Appl. Publ., 4 pp.
     CODEN: USXXCO
```

DT Patent
LA English
IC ICM A61K031-557
ICS A61K031-5377
NCL 514573000; 514235800
CC 1-12 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004082660	A1	20040429	US 2003-429677	20030506
	WO 2004037267	A1	20040506	WO 2003-JP13452	20031022

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	US 2002-420776P	P	20021024
	US 2002-421044P	P	20021025
	US 2003-429677	A	20030506

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004082660	ICM	A61K031-557
	ICS	A61K031-5377
	NCL	514573000; 514235800

AB A method is provided for treating **ocular** hypertension and glaucoma with reduced side effects such as keratoconjunctive disorders and macular edema, which comprises administering an **ophthalmic** composition comprising **latanoprost** as an active ingredient thereof to a subject in need of such treatment, wherein the **ophthalmic** composition contains substantially no benzalkonium chloride.

ST **latanoprost ocular** hypertension glaucoma treatment

IT Quaternary ammonium compounds, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(alkylbenzyldimethyl, chlorides; **latanoprost** for treatment of **ocular** hypertension and glaucoma)

IT **Eye, disease**
(keratoconjunctive disorders; **latanoprost** for treatment of **ocular** hypertension and glaucoma)

IT Antiglaucoma agents
Glaucoma (disease)
(**latanoprost** for treatment of **ocular** hypertension and glaucoma)

IT **Eye, disease**
(macular edema; **latanoprost** for treatment of **ocular** hypertension and glaucoma)

IT Drug delivery systems
(**ophthalmic**; **latanoprost** for treatment of **ocular** hypertension and glaucoma)

IT Drug delivery systems
(solns., **ophthalmic**; **latanoprost** for treatment of **ocular** hypertension and glaucoma)

IT Drug delivery systems
(unit doses; **latanoprost** for treatment of **ocular** hypertension and glaucoma)

IT 60-00-4, EDTA, biological studies **9005-65-6**, Polysorbate 80

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dissolving agent; **latanoprost** for treatment of **ocular** hypertension and glaucoma)

IT 26839-75-8, Timolol **130209-82-4**, **Latanoprost**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**latanoprost** for treatment of **ocular** hypertension and glaucoma)

IT **9005-65-6**, Polysorbate 80
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dissolving agent; **latanoprost** for treatment of **ocular** hypertension and glaucoma)

RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **130209-82-4**, **Latanoprost**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**latanoprost** for treatment of **ocular** hypertension and glaucoma)

RN 130209-82-4 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L116 ANSWER 2 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:331585 HCAPLUS
DN 140:344877
ED Entered STN: 23 Apr 2004
TI **Opthalmic** solution comprising a prostaglandin compound and a **viscosity**-increasing compound
IN **Ueno, Ryuji**
PA **Sucampo Ag, USA**
SO U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-557
ICS A61K009-14
NCL 424486000; 424488000; 514573000
CC 63-5 (Pharmaceuticals)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004076678	A1	20040422	US 2003-644870	20030821 <--

PRAI US 2002-404779P P 20020821 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004076678	ICM	A61K031-557
	ICS	A61K009-14
	NCL	424486000; 424488000; 514573000

OS MARPAT 140:344877

AB The present invention relates to an **ophthalmic** solution comprising a prostaglandin compound and **viscosity**-increasing compd selected from the group consisting of acrylate polymers, polyvinyl alcs., glycerins, cellulose polymers and poly-lactams. The **ophthalmic** solution of the invention can provide elongated duration of the effect when administrated topically to the **eyes** of a patient.

ST opthalmic soln prostaglandin **viscosity** increasing compd

IT **Prostaglandins**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(20-Et, 13,14-dihydro,15-keto; opthalmic solution comprising prostaglandin compound and **viscosity**-increasing compound)

IT **Acrylic polymers, biological studies**
Prostaglandins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(opthalmic solution comprising prostaglandin compound and **viscosity**-increasing compound)

IT **Lactams**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**polylactams**; opthalmic solution comprising prostaglandin compound and **viscosity**-increasing compound)

IT Drug delivery systems
(solns., **ophthalmic**; opthalmic solution comprising prostaglandin compound and **viscosity**-increasing compound)

IT **56-81-5**, Glycerin, biological studies **9002-89-5**
9004-34-6, Cellulose, biological studies **9005-63-4D**,
fatty acyl derivs. **9005-65-6**, Polysorbate 80 **120373-24-2**
120373-36-6 130209-82-4 163075-10-3
369585-22-8 607351-44-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(opthalmic solution comprising prostaglandin compound and **viscosity**-increasing compound)

IT **56-81-5**, Glycerin, biological studies **9002-89-5**
9004-34-6, Cellulose, biological studies **9005-63-4D**,
fatty acyl derivs. **9005-65-6**, Polysorbate 80 **120373-24-2**
120373-36-6 130209-82-4 163075-10-3
369585-22-8 607351-44-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(opthalmic solution comprising prostaglandin compound and **viscosity**-increasing compound)

RN 56-81-5 HCAPLUS

CN 1,2,3-Propanetriol (9CI) (CA INDEX NAME)



RN 9002-89-5 HCAPLUS

CN Ethenol, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 557-75-5
CMF C2 H4 O



RN 9004-34-6 HCAPLUS
CN Cellulose (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9005-63-4 HCAPLUS
CN Sorbitan, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 120373-24-2 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 120373-36-6 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 130209-82-4 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 163075-10-3 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]butyl]cyclopentyl]-, 1-methylethyl ester, (5Z)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 369585-22-8 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxo-5-phenylpentyl)cyclopentyl]-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 607351-44-0 HCAPLUS
CN 5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-N-ethyl-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L116 ANSWER 3 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:220208 HCAPLUS
DN 140:259120
ED Entered STN: 19 Mar 2004
TI Transparent **eye** drops containing **latanoprost**
IN Asada, Hiroyuki; Kimura, Akio
PA Santen Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM A61K031-5575
ICS A61K009-08; A61K047-18; A61K047-34; A61K047-10; A61K047-26; A61P027-06
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022063	A1	20040318	WO 2003-JP11402	20030908
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2004123729	A2	20040422	JP 2003-314865	20030908
PRAI	JP 2002-263030	A	20020909		
	JP 2002-263035	A	20020909		
	JP 2002-263039	A	20020909		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004022063	ICM	A61K031-5575
	ICS	A61K009-08; A61K047-18; A61K047-34; A61K047-10; A61K047-26; A61P027-06
JP 2004123729	FTERM	4C076/AA12; 4C076/BB24; 4C076/CC10; 4C076/DD07E; 4C076/DD22Z; 4C076/DD23D; 4C076/DD26Z; 4C076/DD30Z; 4C076/DD38D; 4C076/DD49R; 4C076/DD67D; 4C076/EE23D; 4C076/FF11; 4C076/FF14; 4C076/FF15; 4C076/FF36; 4C076/FF39; 4C086/AA01; 4C086/AA02; 4C086/DA02; 4C086/MA03; 4C086/MA05; 4C086/MA17; 4C086/MA58; 4C086/NA03; 4C086/NA14; 4C086/ZA33; 4C086/ZC42

AB It is intended to provide an improved formulation of **latanoprost** **eye** drops. Namely, transparent **eye** drops contain

latanoprost as the active ingredient and benzalkonium chloride as a preservative, wherein clouding due to a composition change is prevented by using at least one means selected from the following means; (1) a means of adding a surfactant; (2) a means of using benzalkonium chloride represented by the formula [C6H5CH2N(CH3)2R]Cl (wherein R represents C12 alkyl) as the benzalkonium chloride; and (3) a means of adding a nonionic isotonic agent as an isotonic agent. For example, an **eye** drop solution contained **latanoprost** 0.005, NaH2PO4 0.2, NaCl 0.8, polysorbate-80 0.01, benzalkonium chloride 0.01, and distilled water balance to 100 g.

ST **eyedrop latanoprost** benzalkonium chloride polysorbate

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; transparent **eye** drops containing **latanoprost**)

IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated; transparent **eye** drops containing **latanoprost**)

IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated, ethoxylated; transparent **eye** drops containing **latanoprost**)

IT Drug delivery systems
(solns., **ophthalmic**; transparent **eye** drops containing **latanoprost**)

IT Surfactants
(transparent **eye** drops containing **latanoprost**)

IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transparent **eye** drops containing **latanoprost**)

IT **56-81-5**, Glycerin, biological studies 57-50-1, Sucrose, biological studies 57-55-6, Propylene glycol, biological studies 69-65-8, D-Mannitol 99-20-7, Trehalose 139-07-1, Dimethylbenzyldodecylammonium chloride 9004-99-3, Polyethylene glycol monostearate **9005-65-6**, Polysorbate 80 25322-68-3, Polyethylene glycol **130209-82-4**, **Latanoprost**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transparent **eye** drops containing **latanoprost**)

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Alcon Laboratories Inc; CA 2112027 A 1994 HCAPLUS
(2) Alcon Laboratories Inc; US 5565492 A 1994 HCAPLUS
(3) Alcon Laboratories Inc; EP 603800 A1 1994 HCAPLUS
(4) Alcon Laboratories Inc; AU 9352450 A 1994 HCAPLUS
(5) Alcon Laboratories Inc; US 6166073 A 1997 HCAPLUS
(6) Alcon Laboratories Inc; AU 9676800 A 1997 HCAPLUS
(7) Alcon Laboratories Inc; WO 9723225 A1 1997 HCAPLUS
(8) Merk & Co Inc; US 20020094981 A1 1998
(9) Merk & Co Inc; JP 2002501533 A 1998
(10) Merk & Co Inc; WO 9853809 A1 1998 HCAPLUS
(11) Merk & Co Inc; AU 9876943 A 1998 HCAPLUS
(12) Merk & Co Inc; EP 998277 A1 1998 HCAPLUS
(13) Merk & Co Inc; WO 0004898 A1 2000 HCAPLUS
(14) Merk & Co Inc; EP 1109546 A1 2000 HCAPLUS
(15) Merk & Co Inc; JP 2002521332 A 2000
(16) Merk & Co Inc; AU 9950011 A 2000 HCAPLUS
(17) Sankyo Co Ltd; JP 62-277323 A 1987 HCAPLUS
(18) Santen Pharmaceutical Co Ltd; JP 46-26986 B 1971 HCAPLUS
(19) Santen Pharmaceutical Co Ltd; JP 01-246227 A 1989 HCAPLUS
(20) Santen Pharmaceutical Co Ltd; WO 03063879 A1 2003 HCAPLUS
(21) Santen Pharmaceutical Co Ltd; JP 2003292442 A 2003 HCAPLUS

IT **56-81-5**, Glycerin, biological studies **9005-65-6**,

Polysorbate 80 **130209-82-4**, **Latanoprost**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transparent **eye** drops containing **latanoprost**)
RN 56-81-5 HCAPLUS
CN 1,2,3-Propanetriol (9CI) (CA INDEX NAME)



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 130209-82-4 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L116 ANSWER 4 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:162759 HCAPLUS
DN 140:187439
ED Entered STN: 29 Feb 2004
TI Coated polyunsaturated fatty acid-containing particles for liquid pharmaceuticals
IN Dalziel, Sean Mark; Friedmann, Thomas E.; Schurr, George A.
PA E.I. Du Pont de Nemours and Company, USA
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C10M
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004016720	A2	20040226	WO 2003-US25873	20030814 <--
WO 2004016720	A3	20040408		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,

TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG
PRAI US 2002-403598P P 20020814 <--
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004016720	ICM	C10M

AB A process for coating a polyunsatd. fatty acid (PUFA)-containing carrier particle or a PUFA matrix particle, or a liquid pharmaceutical-containing carrier particle or a liquid pharmaceutical matrix particle. Also disclosed are such particles made by the process of the invention and foods, pharmaceuticals, beverages, nutritional supplements, infant formula, pet food and animal feed which incorporate such particles. The oil-coated silica particles were coated to produce a barrier layer of solid gelatin. Such a solid coating on an oil materials is useful as a barrier to the undesirable effects of oxidation and it improves the handling characteristics of of the oil-coated particles.

ST coated polyunsatd fatty acid liq pharmaceutical

IT Hormone replacement therapy
(agents for; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Diagnosis
(agents; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Hormones, animal, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anabolic steroids; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Thyroid gland
(antithyroid agents; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Heart, disease
(arrhythmia; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Skin preparations (pharmaceutical)
(astringents; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Drug delivery systems
(buccal; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Ion channel blockers
(calcium; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Glycosides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cardiac; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Adrenoceptor agonists
Adrenoceptor antagonists
Analgesics
Antacids
Anthelmintics
Anti-inflammatory agents
Antiarrhythmics
Antibiotics
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents

Antidiarrheals
Antiemetics
Antihistamines
Antihypertensives
Antiobesity agents
Antioxidants
Antipsychotics
Antitumor agents
Antitussives
Antiviral agents
Anxiety
Anxiolytics
Asthma
Beverages
Binders
Bitterness
Bronchodilators
Cholinergic agonists
Cholinergic antagonists
Coating materials
Contraceptives
Convulsion
Cough
Diabetes mellitus
Diarrhea
Diuresis
Diuretics
Dopamine agonists
Dyes
Electrolytes
Epilepsy
Feed
Flavoring materials
Food
Fungicides
Hemorrhage
Hemostatics
Human
Hydrocolloids
Hypertension
Hypnotics and Sedatives
Immunosuppressants
Immunosuppression
Inflammation
Laxatives
Lubricants
Muscarinic antagonists
Muscle relaxants
Mycosis
Neoplasm
Nervous system stimulants
Obesity
Odor and Odorous substances
Pain
Protozoacides
Psychostimulants
Sleep
Surfactants
Thrombosis
Thyroid gland, disease
Vaccines
Vasodilation
Vasodilators

Vomiting
(coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT **Acrylic polymers, biological studies**
Alditols
Antibodies and Immunoglobulins
Bile acids
Carbohydrates, biological studies
Corticosteroids, biological studies
Disaccharides
Enzymes, biological studies
Lipids, biological studies
Minerals, biological studies
Monosaccharides
Oligosaccharides, biological studies
Peptides, biological studies
Polymers, biological studies
Polyoxyalkylenes, biological studies
Polysaccharides, biological studies
Prostaglandins
Proteins
Salts, biological studies
Sex hormones
Shellac
Sulfonamides
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Intestine, disease
(constipation; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Mental disorder
(depression; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(emulsifying; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glycolide-based; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Milk substitutes
(human; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Drug delivery systems
(implants; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Sexual behavior
(impotence, drugs for treatment of; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Animal virus
Protozoa
(infection with; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Drug delivery systems
(inhalants; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactic acid-based; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactide; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Drug delivery systems
(liqs.; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Drug delivery systems
(nasal; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Drug delivery systems
(**ophthalmic**; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Drug delivery systems
(oral; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Drug delivery systems
(parenterals; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyhydric; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd.; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Intestinal bacteria
(probiotic; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Mental disorder
(psychosis; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Drug delivery systems
(rectal; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soybean; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Muscle, disease
(spasm; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Muscle relaxants
(spasmolytics; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Drug delivery systems
(sublingual; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Diet
(supplements; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Drug delivery systems
(topical; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Drug delivery systems
(transdermal; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Drug delivery systems
(vaginal; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT Adrenoceptor antagonists
(β-; coated polyunsatd. fatty acid-containing particles for liquid

pharmaceuticals)
IT 57-11-4, Stearic acid, biological studies 57-50-1, Sucrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 69-89-6D, Xanthine, derivs. 77-93-0, Triethyl citrate **79-41-4D**, Methacrylic acid, esters, polymers 102-76-1, Triacetin 109-43-3, Dibutyl sebacate 151-21-3, Sodium lauryl sulfate, biological studies 471-34-1, Calcium carbonate, biological studies 506-26-3, γ-Linolenic acid 506-32-1, Arachidonic acid 557-04-0 577-11-7, Sodium docusate 1783-84-2, Dihomoγ-Linolenic acid 4070-80-8, Sodium stearyl fumarate 7757-93-9, Dicalcium phosphate 9002-88-4, Polyethylene 9003-39-8, Polyvinylpyrrolidone **9004-34-6D**, Cellulose, derivs. **9004-38-0**, Cellulose acetate phthalate **9004-57-3**, Ethyl cellulose **9004-64-2**, Hydroxypropyl cellulose **9004-65-3**, Hydroxypropyl methyl cellulose **9004-67-5**, MEthyl cellulose 9005-25-8, Starch, biological studies **9005-65-6**, Tween 80 9063-38-1, Sodium starch glycolate 13463-67-7, Titanium oxide, biological studies 14807-96-6, Talc, biological studies 25167-62-8, Docosahexaenoic acid 25322-68-3, Polyethylene glycol 25378-27-2, Eicosapentaenoic acid 26009-03-0, Polyglycolide 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26100-51-6, Polylactic acid 26202-08-4, Polyglycolide 26680-10-4, Polylactide 74811-65-7, Croscarmellose sodium 105287-09-0, Aquateric 106392-12-5, Poloxamer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT 7631-86-9, Fumed silica, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(colloidal; coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
IT **79-41-4D**, Methacrylic acid, esters, polymers **9004-34-6D**, Cellulose, derivs. **9004-38-0**, Cellulose acetate phthalate **9004-57-3**, Ethyl cellulose **9004-64-2**, Hydroxypropyl cellulose **9004-65-3**, Hydroxypropyl methyl cellulose **9004-67-5**, MEthyl cellulose **9005-65-6**, Tween 80
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coated polyunsatd. fatty acid-containing particles for liquid pharmaceuticals)
RN 79-41-4 HCAPLUS
CN 2-Propenoic acid, 2-methyl- (9CI) (CA INDEX NAME)



RN 9004-34-6 HCAPLUS
CN Cellulose (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9004-38-0 HCAPLUS
CN Cellulose, acetate hydrogen 1,2-benzenedicarboxylate (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 88-99-3
CMF C8 H6 O4



CM 3

CRN 64-19-7
CMF C2 H4 O2



RN 9004-57-3 HCAPLUS
CN Cellulose, ethyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 64-17-5
CMF C2 H6 O



RN 9004-64-2 HCAPLUS
CN Cellulose, 2-hydroxypropyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9004-65-3 HCAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9004-67-5 HCAPLUS
CN Cellulose, methyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L116 ANSWER 5 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:60341 HCAPLUS
DN 140:117406
ED Entered STN: 26 Jan 2004
TI Liquid dosage compositions of stable nanoparticulate drugs
IN Bosch, William H.; Hilborn, Matthew R.; Hovey, Douglas C.; Kline, Laura J.; Lee, Robert W.; Pruitt, John D.; Ryde, Niels P.; Ryde, Tuula A.; Xu, Shuqian
PA Elan Pharma International, Ltd, Ire.
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K047-02
ICS A61K047-10; A61K047-26; A61K009-10; A61K009-14; A61K031-192; A61K031-58
CC 63-6 (Pharmaceuticals)
FAN.CNT 15

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004006959	A1	20040122	WO 2003-US22187	20030716 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-396530P P 20020716 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004006959	ICM	A61K047-02
	ICS	A61K047-10; A61K047-26; A61K009-10; A61K009-14; A61K031-192; A61K031-58

AB The present invention relates to liquid dosage compns. of stable nanoparticulate drugs. The liquid dosage compns. of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the drug. Thus, an aqueous nanoparticulate colloidal dispersion (NCD) comprising drug 32.5 Copovidone 6.5, and dioctyl sodium sulfosuccinate 0.464% by weight was prepared by milling for 3.8 h under high energy milling conditions. The final mean particle size (by weight) of the drug particles was 161 nm. The concentrated NCD was then diluted with preserved water and glycerol (the osmotically active crystal growth inhibitor) to 0.5-3.0% drug.

ST liq dosage stable nanoparticulate drug
IT Intestine, disease
(Crohn's; liquid dosage compns. of stable nanoparticulate drugs)
IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C16-18, ethoxylated; liquid dosage compns. of stable nanoparticulate drugs)
IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C16-18; liquid dosage compns. of stable nanoparticulate drugs)
IT Arthritis
(Reiter's syndrome; liquid dosage compns. of stable nanoparticulate

drugs)
IT Drug delivery systems
(aerosols; liquid dosage compns. of stable nanoparticulate drugs)
IT Diagnosis
(agents; liquid dosage compns. of stable nanoparticulate drugs)
IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkyl group-terminated; liquid dosage compns. of stable nanoparticulate drugs)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; liquid dosage compns. of stable nanoparticulate drugs)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkyltrimethyl, chlorides; liquid dosage compns. of stable nanoparticulate drugs)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkyltrimethyl, ethoxylated; liquid dosage compns. of stable nanoparticulate drugs)
IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(animal, marine; liquid dosage compns. of stable nanoparticulate drugs)
IT Spinal column, disease
(ankylosing spondylitis; liquid dosage compns. of stable nanoparticulate drugs)
IT Polyethers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aromatic, sulfonates; liquid dosage compns. of stable nanoparticulate drugs)
IT Heart, disease
(arrhythmia; liquid dosage compns. of stable nanoparticulate drugs)
IT Skin preparations (pharmaceutical)
(astringents; liquid dosage compns. of stable nanoparticulate drugs)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzyl-C12-18-alkyldimethyl, chlorides; liquid dosage compns. of stable nanoparticulate drugs)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzyl-C14-18-alkyldimethyl, chlorides; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(bioadhesive; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(buccal; liquid dosage compns. of stable nanoparticulate drugs)
IT Joint, anatomical
(bursa, disease, bursitis; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(capsules; liquid dosage compns. of stable nanoparticulate drugs)
IT Lipids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cationic; liquid dosage compns. of stable nanoparticulate drugs)
IT Uterus, neoplasm
(cervix; liquid dosage compns. of stable nanoparticulate drugs)
IT Bronchi, disease
(chronic bronchitis; liquid dosage compns. of stable nanoparticulate drugs)
IT Lung, disease
(chronic obstructive; liquid dosage compns. of stable nanoparticulate drugs)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coco alkyl(hydroxyethyl)dimethyl, chlorides; liquid dosage compns. of stable nanoparticulate drugs)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coco alkylbis(hydroxyethyl)methyl, chlorides; liquid dosage compns. of stable nanoparticulate drugs)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coco alkyltrimethyl, bromides; liquid dosage compns. of stable nanoparticulate drugs)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coco alkyltrimethyl, chlorides; liquid dosage compns. of stable nanoparticulate drugs)
IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coco, esters with sucrose; liquid dosage compns. of stable nanoparticulate drugs)
IT Intestine, disease
(colitis; liquid dosage compns. of stable nanoparticulate drugs)
IT Imaging agents
(contrast; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(controlled-release; liquid dosage compns. of stable nanoparticulate drugs)
IT Mental disorder
(depression; liquid dosage compns. of stable nanoparticulate drugs)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dialkyldimethyl, chlorides; liquid dosage compns. of stable nanoparticulate drugs)
IT Tendon
(disease, tendinitis; liquid dosage compns. of stable nanoparticulate drugs)
IT Uterus, disease
(endometriosis; liquid dosage compns. of stable nanoparticulate drugs)
IT Uterus, neoplasm
(endometrium; liquid dosage compns. of stable nanoparticulate drugs)
IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(esters; liquid dosage compns. of stable nanoparticulate drugs)
IT Castor oil
Phospholipids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated; liquid dosage compns. of stable nanoparticulate drugs)
IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(evening primrose; liquid dosage compns. of stable nanoparticulate drugs)
IT Fruit
Vegetable
(exts.; liquid dosage compns. of stable nanoparticulate drugs)
IT Heart, disease
(failure; liquid dosage compns. of stable nanoparticulate drugs)
IT Intestine, neoplasm
(familial polyposis; liquid dosage compns. of stable nanoparticulate drugs)
IT Muscle, disease
(fibromyalgia; liquid dosage compns. of stable nanoparticulate drugs)
IT Stomach, disease
(gastritis; liquid dosage compns. of stable nanoparticulate drugs)
IT Digestive tract, disease

(gastroenteritis; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(gels; liquid dosage compns. of stable nanoparticulate drugs)
IT Tea products
(green; liquid dosage compns. of stable nanoparticulate drugs)
IT Carboxylic acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy; liquid dosage compns. of stable nanoparticulate drugs)
IT Animal virus
Eubacteria
Fungi
(infection with; liquid dosage compns. of stable nanoparticulate drugs)
IT Lung, disease
(infection; liquid dosage compns. of stable nanoparticulate drugs)
IT Intestine, disease
(inflammatory; liquid dosage compns. of stable nanoparticulate drugs)
IT Crystal growth
Thyroid gland
(inhibitors; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(injections, i.p.; liquid dosage compns. of stable nanoparticulate drugs)
IT Rheumatoid arthritis
(juvenile; liquid dosage compns. of stable nanoparticulate drugs)
IT AIDS (disease)
Acne
Adrenoceptor agonists
Allergy
Allergy inhibitors
Aloe barbadensis
Alzheimer's disease
Analgesics
Anorexia
Anthelmintics
Anti-AIDS agents
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarrhythmics
Antiarthritics
Antiasthmatics
Antibacterial agents
Antibiotics
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antiemetics
Antihistamines
Antihypertensives
Antimigraine agents
Antiobesity agents
Antioxidants
Antirheumatic agents
Antitumor agents
Antitussives
Antiviral agents
Anxiety
Anxiolytics
Arthritis
Asthma
Blood products
Blood substitutes
Cachexia
Cardiovascular agents

Cardiovascular system, disease
Castration
Cholinergic agonists
Commiphora mukul
Cough
Cystic fibrosis
Diabetes mellitus
Diuresis
Diuretics
Dopamine agonists
Drug bioavailability
Drug bioequivalence
Dysmenorrhea
Dyspepsia
Emphysema
Epilepsy
Fish
Food
Food additives
Food poisoning
Fungicides
Gout
Hemorrhage
Hemostatics
Herb
Hirsutism
Hormone replacement therapy
Human
Hypertension
Hypnotics and Sedatives
Imaging agents
Immunosuppressants
Immunosuppression
Inflammation
Inotropics
Kidney, disease
Kidney, neoplasm
Mammary gland, neoplasm
Motion sickness
Muscarinic antagonists
Muscle contraction
Muscle relaxants
Neoplasm
Obesity
Osteoarthritis
Osteoporosis
Pain
Parathyroid gland
Particle size distribution
Prostate gland, neoplasm
Radiopharmaceuticals
Respiratory distress syndrome
Rheumatoid arthritis
Shear
Size reduction
Sleep
Solubility
Stabilizing agents
Storage
Thrombosis
Transplant and Transplantation
Transplant rejection
Uterus, neoplasm

Vasodilation
Vasodilators
Viscosity
Vomiting
(liquid dosage compns. of stable nanoparticulate drugs)

IT Glycols, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Alditols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Amine oxides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Amines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Amino acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Biopolymers
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Carbohydrates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Caseins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Corticosteroids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Disaccharides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Flavonoids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Gelatins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Glycerophospholipids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Minerals, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Monosaccharides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Phosphates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Phosphatidylserines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

IT Phosphonium compounds
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT Polysaccharides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT **Prostaglandins**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT Proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT Safflower oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT Salts, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT Sex hormones
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT Sulfonium compounds
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(liqs.; liquid dosage compns. of stable nanoparticulate drugs)
IT Headache
(migraine; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(nanoparticles; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(nasal; liquid dosage compns. of stable nanoparticulate drugs)
IT Anti-inflammatory agents
(nonsteroidal; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(ointments, creams; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(ointments; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(**ophthalmic**; liquid dosage compns. of stable nanoparticulate drugs)
IT Contraceptives
Drug delivery systems
(oral; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(parenterals; liquid dosage compns. of stable nanoparticulate drugs)
IT Nerve, disease

(peripheral, injury; liquid dosage compns. of stable nanoparticulate drugs)
IT Polyoxyalkylenes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(phenolic; liquid dosage compns. of stable nanoparticulate drugs)
IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phospholipid derivs.; liquid dosage compns. of stable nanoparticulate drugs)
IT Nutrients
(plant; liquid dosage compns. of stable nanoparticulate drugs)
IT Phenolic resins, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polyoxyalkylene-; liquid dosage compns. of stable nanoparticulate drugs)
IT Menopause
(postmenopause; liquid dosage compns. of stable nanoparticulate drugs)
IT Intestinal bacteria
(probiotic; liquid dosage compns. of stable nanoparticulate drugs)
IT Arthritis
(psoriatic arthritis; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(pulmonary; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(rectal; liquid dosage compns. of stable nanoparticulate drugs)
IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(regulating agents; liquid dosage compns. of stable nanoparticulate drugs)
IT Amines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(salts; liquid dosage compns. of stable nanoparticulate drugs)
IT Connective tissue, disease
(scleroderma; liquid dosage compns. of stable nanoparticulate drugs)
IT Linum usitatissimum
(seeds; liquid dosage compns. of stable nanoparticulate drugs)
IT Diet
(supplements; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(suspensions, oral; liquid dosage compns. of stable nanoparticulate drugs)
IT Lupus erythematosus
(systemic; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(tablets; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(topical; liquid dosage compns. of stable nanoparticulate drugs)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tri-C8-10-alkylmethyl, chlorides; liquid dosage compns. of stable nanoparticulate drugs)
IT Drug delivery systems
(vaginal; liquid dosage compns. of stable nanoparticulate drugs)
IT Adrenoceptor antagonists
(β-; liquid dosage compns. of stable nanoparticulate drugs)
IT 13598-36-2D, Phosphonic acid, alkylidenebis- derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Bisphosphonate; liquid dosage compns. of stable nanoparticulate drugs)
IT 7631-86-9, Silica, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(colloidal; liquid dosage compns. of stable nanoparticulate drugs)

IT 9004-06-2, Elastase 329900-75-6, COX-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; liquid dosage compns. of stable nanoparticulate drugs)
IT 110-54-3, Hexane, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)
IT 50-35-1, Thalidomide 50-44-2, Mercaptopurine 50-53-3, Chlorpromazine, biological studies 50-78-2, Acetylsalicylic acid 50-99-7, Glucose, biological studies 52-53-9, Verapamil **56-81-5**, Glycerol, biological studies 56-85-9, Glutamine, biological studies 57-09-0, Hexadecyltrimethylammonium bromide 57-11-4, Stearic acid, biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 57-55-6, Propylene glycol, biological studies 57-88-5, Cholesterol, biological studies 58-32-2, Dipyridamole 59-30-3, Folic acid, biological studies 62-49-7D, Choline, esters 63-42-3, Lactose 64-17-5, Ethanol, biological studies 67-45-8, Furazolidone 69-65-8, Mannitol 69-89-6D, Xanthine, derivs. 73-31-4, Melatonin 75-65-0, biological studies 80-74-0, Acetylsulfisoxazole 87-99-0, Xylitol 99-20-7, Trehalose 102-71-6, Triethanolamine, biological studies 110-86-1D, Pyridine, quaternized, salts 112-00-5, Lauryltrimethylammonium chloride 123-03-5, CPC 129-03-3, Cyproheptadine 132-17-2, Benztropine mesylate 134-32-7D, 1-Naphthylamine, alkyldimethylammonium salts 139-07-1, Lauryldimethylbenzylammonium chloride 140-72-7, Cetylpyridinium bromide 143-67-9, Vinblastine sulfate 148-79-8, Thiabendazole 151-21-3, SDS, biological studies 154-42-7, Thioguanine 288-32-4D, Imidazole, quaternized, salts 303-53-7, Cyclobenzaprine 396-01-0, Triamterene 500-92-5, Proguanil 502-65-8, Lycopene 645-05-6, Altretamine 846-50-4, Temazepam 1119-94-4, Dodecyltrimethylammonium bromide 1119-97-7, Tetradecyltrimethylammonium bromide 1200-22-2, Lipoic acid 1327-43-1, Magnesium aluminum silicate 1592-23-0, Calcium Stearate 1643-19-2, Tetrabutylammonium bromide 1951-25-3, Amiodarone 1977-10-2, Loxapine 2062-78-4, Pimozide 2082-84-0, Decyltrimethylammonium bromide 2609-46-3, Amiloride 3416-24-8, Glucosamine 3458-28-4, Mannose 4205-90-7, Clonidine 4342-03-4, Dacarbazine 5137-55-3, Methyltrioctylammonium chloride 5350-41-4, Benzyltrimethylammonium bromide 7173-51-5, Dimethyldidecylammonium chloride 7281-04-1, Lauryldimethylbenzylammonium bromide 7447-40-7, Potassium chloride (KCl), biological studies 7647-14-5, Sodium chloride, biological studies 7786-30-3, Magnesium chloride (MgCl2), biological studies 9000-01-5, Gum acacia 9000-30-0D, Guar gum, cationic derivs. 9000-65-1, Tragacanth gum 9001-63-2, Lysozyme **9002-89-5**, Poly(vinyl alcohol) 9003-39-8, Polyvinylpyrrolidone **9004-32-4 9004-34-6**, Cellulose, biological studies 9004-54-0, Dextran, biological studies **9004-62-0**, Hydroxyethyl cellulose **9004-64-2**, Hydroxypropyl cellulose **9004-65-3**, Hypromellose **9004-67-5**, Methyl cellulose 9004-99-3, Polyethylene glycol stearate 9005-32-7, Alginic acid 9007-12-9, Calcitonin 9007-27-6, Chondroitin 9011-14-7, Poly(methyl methacrylate) 9011-14-7D, Poly(methyl methacrylate), hydrolyzed, trimethylammonium salts **9050-04-8**, Cellulose, carboxymethyl ether, calcium salt **9050-31-1**, Hydroxypropyl methyl cellulose phthalate 10118-90-8, Minocycline 12441-09-7D, Sorbitan, esters 13292-46-1, Rifampin 16679-58-6, Desmopressin 18186-71-5, Dodecyltriethylammonium bromide 24280-93-1 25086-89-9, Vinyl acetate-1-vinyl-2-pyrrolidone copolymer 25301-02-4, Ethylene oxide-formaldehyde-4-(1,1,3,3-Tetramethylbutyl)phenol copolymer 25322-68-3, Polyethylene glycol 25322-68-3D, Polyethylene glycol, phospholipid derivs. 26062-79-3, Poly(diallyldimethylammonium chloride) 27195-16-0, Sucrose distearate 27321-96-6, Polyethylene glycol cholesteryl ether 28228-56-0 28679-24-5, Dodecylbenzyltriethylammonium chloride 28981-97-7, Alprazolam 29094-61-9, Glipizide 29767-20-2, Teniposide 29836-26-8,

n-Octyl-β-D-glucopyranoside 31431-39-7, Mebendazole 31566-31-1, Glyceryl monostearate 33419-42-0, Etoposide 34911-55-2, Bupropion 36735-22-5, Quazepam 37318-31-3, Sucrose stearate 38443-60-6, Decyltriethylammonium chloride 39809-25-1, Penciclovir 42399-41-7, Diltiazem 51264-14-3, Amsacrine 51569-39-2, Olin 10G 52128-35-5, Trimetrexate 52467-63-7, Tricetylmethylammonium chloride 55008-57-6 55268-75-2, Cefuroxime 55348-40-8, Triton X-200 58846-77-8, n-Decyl β-D-glucopyranoside 59080-45-4, n-Hexyl β-D-glucopyranoside 59122-55-3, n-DoDecyl β-D-glucopyranoside 59277-89-3, Acyclovir 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 66085-59-4, Nimodipine 69227-93-6, n-DoDecyl β-D-maltoside 69984-73-2, n-Nonyl β-D-glucopyranoside 70458-96-7, Norfloxacin 72509-76-3, Felodipine 72558-82-8, Ceftazidime 72559-06-9, Rifabutin 73590-58-6, Omeprazole 76095-16-4, Enalapril maleate 76420-72-9, Enalaprilat 76824-35-6, Famotidine 78617-12-6, n-Heptyl β-D-glucopyranoside 79617-96-2, Sertraline 79794-75-5, Loratadine 81098-60-4, Cisapride 81103-11-9, Clarithromycin 81409-90-7, Cabergoline **81859-24-7**, Polyquat 10 82494-09-5, n-Decyl β-D-maltoside 84449-90-1, Raloxifene 85261-19-4, Nonanoyl-N-methylglucamide 85261-20-7, Decanoyl-N-methylglucamide 85316-98-9 85618-20-8, n-Heptyl β-D-thioglucopyranoside 85618-21-9, n-Octyl-β-D-thioglucopyranoside 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 87679-37-6, Trandolapril 91161-71-6, Terbinafine 95233-18-4, Atovaquone 97322-87-7, Troglitazone 100286-97-3, Milrinone lactate 101397-87-9, D-Glucitol, 1-deoxy-1-[methyl(1-oxoheptyl)amino]- 103577-45-3, Lansoprazole 104987-11-3, Tacrolimus 106266-06-2, Risperidone 106392-12-5, Pluronic 107397-59-1, Tetronic 150R8 110617-70-4, Poloxamine 113665-84-2, Clopidogrel 115956-12-2, Dolasetron 127666-00-6 127779-20-8, Saquinavir 132539-06-1, Olanzapine 136817-59-9, Delavirdine 138402-11-6, Irbesartan 139481-59-7, Candesartan 139755-83-2, Sildenafil 144034-80-0, Rizatriptan 145599-86-6, Cerivastatin 147059-72-1, Trovafloxacin 159989-65-8, Nelfinavir mesylate 283158-20-3 329326-68-3, p-Isononylphenoxypolyglycidol 503178-50-5 608094-65-1, PEG-vitamin A 630400-66-7 630400-67-8 634601-99-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Nanosystems Llc; WO 9624335 A 1996 HCAPLUS
(2) Rajagopalan, N; US 5298262 A 1994 HCAPLUS
(3) Ruddy, S; US 5585108 A 1996 HCAPLUS
(4) Sterling Winthrop Inc; EP 0601619 A 1994 HCAPLUS

IT **56-81-5**, Glycerol, biological studies **9002-89-5**, Poly(vinyl alcohol) **9004-32-4 9004-34-6**, Cellulose, biological studies **9004-62-0**, Hydroxyethyl cellulose **9004-64-2**, Hydroxypropyl cellulose **9004-65-3**, Hypromellose **9004-67-5**, Methyl cellulose **9050-04-8**, Cellulose, carboxymethyl ether, calcium salt **9050-31-1**, Hydroxypropyl methyl cellulose phthalate **81859-24-7**, Polyquat 10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liquid dosage compns. of stable nanoparticulate drugs)

RN 56-81-5 HCAPLUS
CN 1,2,3-Propanetriol (9CI) (CA INDEX NAME)



RN 9002-89-5 HCAPLUS
CN Ethenol, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 557-75-5
CMF C2 H4 O



RN 9004-32-4 HCAPLUS
CN Cellulose, carboxymethyl ether, sodium salt (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
CMF C2 H4 O3



RN 9004-34-6 HCAPLUS
CN Cellulose (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9004-62-0 HCAPLUS
CN Cellulose, 2-hydroxyethyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 107-21-1
CMF C2 H6 O2



RN 9004-64-2 HCAPLUS
CN Cellulose, 2-hydroxypropyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified

CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9004-65-3 HCAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9004-67-5 HCAPLUS
CN Cellulose, methyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

H_3C-OH

RN 9050-04-8 HCAPLUS
CN Cellulose, carboxymethyl ether, calcium salt (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
CMF C2 H4 O3



RN 9050-31-1 HCAPLUS
CN Cellulose, hydrogen 1,2-benzenedicarboxylate, 2-hydroxypropyl methyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 88-99-3
CMF C8 H6 O4



CM 3

CRN 67-56-1
CMF C H4 O

H_3C-OH

CM 4

CRN 57-55-6
CMF C3 H8 O2



RN 81859-24-7 HCAPLUS
CN Cellulose, 2-hydroxyethyl 2-[2-hydroxy-3-(trimethylammonio)propoxy]ethyl 2-hydroxy-3-(trimethylammonio)propyl ether, chloride (9CI) (CA INDEX NAME)

CM 1

CRN 170553-71-6
CMF C8 H20 N O3 . x C6 H16 N O2 . x C2 H6 O2 . x Unspecified

CM 2

CRN 170344-46-4
CMF C8 H20 N O3



CM 3

CRN 44814-66-6
CMF C6 H16 N O2



CM 4

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 5

CRN 107-21-1
CMF C2 H6 O2



L116 ANSWER 6 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:609847 HCAPLUS
DN 139:128062
ED Entered STN: 08 Aug 2003
TI Method of enhancing hair growth using cyclopentane heptanoic acid compounds
IN Woodward, David F.; Vandenburgh, Amanda M.
PA Allergan, Inc., USA
SO U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-557
ICS A61K031-558; A61K007-06
NCL 424070100; 514568000; 514430000; 514277000; 514449000
CC 1-12 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003147823	A1	20030807	US 2003-345788	20030115 <--
WO 2003066008	A1	20030814	WO 2003-US3363	20030203 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-354425P	P	20020204 <--	
US 2003-345788	A	20030115	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003147823	ICM	A61K031-557
	ICS	A61K031-558; A61K007-06
	NCL	424070100; 514568000; 514430000; 514277000; 514449000

OS MARPAT 139:128062
GI



I

AB Methods and compns. for stimulating the growth of hair are disclosed wherein said compns. include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound I (dashed bonds represent single or double bond which can be in the cis or trans configuration; A = alkylene or alkenylene radical; B = cycloalkyl, aryl; Z = O; X = N(R4)2; R4 = H, lower alkyl, etc.; R1, R2 = O, OH, O(CO)R6; and R6 = C1-20 (un)saturated acyclic hydrocarbon, etc.). Such compns. are used in treating the skin or scalp

of a human or non-human animal. Bimatoprost is preferred for this treatment. In a patient treated for glaucoma with bimatoprost, the **eyelashes** had increased growth.

ST cyclopentane heptanoate compd enhancing hair growth; **eyelash** growth bimatoprost

IT Drug delivery systems
(aerosols; cyclopentane heptanoic acid compds. for enhancing hair growth)

IT Alopecia
Animal
Hair
Human
Mammalia
Scalp
Skin
(cyclopentane heptanoic acid compds. for enhancing hair growth)

IT Paraffin oils
Petrolatum
Wool wax
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclopentane heptanoic acid compds. for enhancing hair growth)

IT **Eye**
(**eyelash**; cyclopentane heptanoic acid compds. for enhancing hair growth)

IT Hair
(follicle; cyclopentane heptanoic acid compds. for enhancing hair growth)

IT Hair preparations
(growth stimulants; cyclopentane heptanoic acid compds. for enhancing hair growth)

IT Drug delivery systems
(lotions; cyclopentane heptanoic acid compds. for enhancing hair growth)

IT Drug delivery systems
(ointments, creams; cyclopentane heptanoic acid compds. for enhancing hair growth)

IT Drug delivery systems
(powders, topical, dusting; cyclopentane heptanoic acid compds. for enhancing hair growth)

IT Drug delivery systems
(solns.; cyclopentane heptanoic acid compds. for enhancing hair growth)

IT Waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spermaceti; cyclopentane heptanoic acid compds. for enhancing hair growth)

IT Drug delivery systems
(topical; cyclopentane heptanoic acid compds. for enhancing hair growth)

IT 5763-58-6D, Cyclopentane heptanoic acid, cycloalkyl or arylalkyl compds. **155206-00-1**, Bimatoprost **155206-00-1D**, Bimatoprost, acid addition salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclopentane heptanoic acid compds. for enhancing hair growth)

IT 57-55-6, Propylene glycol, biological studies 64-17-5, Ethanol, biological studies 75-71-8, Dichlorodifluoromethane 99-76-3, Methylparaben 872-50-4, N-Methyl pyrrolidone, biological studies 1314-13-2, Zinc oxide, biological studies 1320-37-2, Dichlorotetrafluoroethane 7732-18-5, Water, biological studies 8011-96-9, Calamine 8049-07-8, Tegacid **9005-65-6**, Polysorbate 80 14807-96-6, Talc, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclopentane heptanoic acid compds. for enhancing hair growth)

IT **155206-00-1**, Bimatoprost **155206-00-1D**, Bimatoprost, acid addition salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclopentane heptanoic acid compds. for enhancing hair growth)
RN 155206-00-1 HCAPLUS
CN 5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 155206-00-1 HCAPLUS
CN 5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **9005-65-6**, Polysorbate 80
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclopentane heptanoic acid compds. for enhancing hair growth)
RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L116 ANSWER 7 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:491033 HCAPLUS
DN 139:47185
ED Entered STN: 27 Jun 2003
TI Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
IN May, Jesse A.
PA Alcon, Inc., Switz.

SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-34
ICS C07D307-81; C07D307-82
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003051352	A1	20030626	WO 2002-US38908	20021205 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
EP 1461030	A1	20040929	EP 2002-784741	20021205 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRAI US 2001-340361P	P	20011214 <--		
WO 2002-US38908	W	20021205		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003051352	ICM	A61K031-34
	ICS	C07D307-81; C07D307-82

AB The present invention provides novel compns. containing the compds. of the invention in a pharmaceutically acceptable excipient and methods for using the compns. for lowering **intraocular** pressure.

ST aminoalkyl benzofuranol compd glaucoma **intraocular** pressure

IT Glutamate antagonists
(NMDA antagonists; aminoalkyl benzofuranol compds. for treatment of glaucoma)

IT **Viscosity**
(agents for; aminoalkyl benzofuranol compds. for treatment of glaucoma)

IT Antiglaucoma agents
Eye
Surfactants
(aminoalkyl benzofuranol compds. for treatment of glaucoma)

IT **Prostaglandins**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoalkyl benzofuranol compds. for treatment of glaucoma)

IT Ion channel blockers
(calcium; aminoalkyl benzofuranol compds. for treatment of glaucoma)

IT Nervous system agents
(miotics; aminoalkyl benzofuranol compds. for treatment of glaucoma)

IT Cytoprotective agents
(neuroprotective; aminoalkyl benzofuranol compds. for treatment of glaucoma)

IT Drug delivery systems
(solns., **ophthalmic**; aminoalkyl benzofuranol compds. for treatment of glaucoma)

IT Drug delivery systems
(suspensions, **ophthalmic**; aminoalkyl benzofuranol compds. for treatment of glaucoma)

IT Adrenoceptor agonists
(α2-; aminoalkyl benzofuranol compds. for treatment of glaucoma)

IT Adrenoceptor antagonists

(β-; aminoalkyl benzofuranol compds. for treatment of glaucoma)
IT 9003-39-8, Polyvinylpyrrolidone **9004-62-0**, Hydroxyethyl cellulose **9004-65-3**, Hydroxypropyl methyl cellulose **9004-67-5**, Methyl cellulose **37353-59-6**, Hydroxymethyl cellulose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoalkyl benzofuranol compds. for treatment of glaucoma)
IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; aminoalkyl benzofuranol compds. for treatment of glaucoma)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Eli Lily And Company; WO 0044737 A1 2000 HCAPLUS
(2) Grinev; CAPLUS NO 1984:68106 1983
(3) Ogawa; US 5539974 A1 1996
IT **9004-62-0**, Hydroxyethyl cellulose **9004-65-3**, Hydroxypropyl methyl cellulose **9004-67-5**, Methyl cellulose **37353-59-6**, Hydroxymethyl cellulose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminoalkyl benzofuranol compds. for treatment of glaucoma)
RN 9004-62-0 HCAPLUS
CN Cellulose, 2-hydroxyethyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 107-21-1
CMF C2 H6 O2



RN 9004-65-3 HCAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9004-67-5 HCAPLUS
CN Cellulose, methyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



RN 37353-59-6 HCAPLUS
CN Cellulose, hydroxymethyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 463-57-0
CMF C H4 O2



L116 ANSWER 8 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:490986 HCAPLUS
DN 139:63347
ED Entered STN: 27 Jun 2003
TI Substituted 5-hydroxyindole compounds for the treatment of **glaucoma**
IN May, Jesse A.; Dantanarayana, Anura P.
PA Alcon, Inc., Switz.; Namil, Abdelmoula; Sharif, Najam A.; Zinke, Paul W.; Dean, Thomas R.
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA English

IC ICM A61K
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051291	A2	20030626	WO 2002-US38625	20021205 <--
	WO 2003051291	A3	20031023		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR

PRAI US 2001-340445P P 20011214 <--
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003051291	ICM	A61K

OS MARPAT 139:63347
AB The present invention provides novel compds. with 5-HT2 agonist activity, compns. containing the compds. and methods of their use to lower **intraocular** pressure and/or provide neuroprotection. CNS activity of bufotenine fumarate was studied in mice.
ST hydroxyindole compd **glaucoma intraocular** pressure neuroprotection; bufotenine **glaucoma intraocular** pressure neuroprotection
IT 5-HT agonists
(5-HT2A; substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT Glutamate antagonists
(NMDA antagonists; substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT Mitosis
(agents for; substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT Ion channel blockers
(calcium; substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT Cytoprotective agents
(neuroprotective; substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT Drug delivery systems
(solns., **ophthalmic**; substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT Antiglaucoma agents
Surfactants
Viscosity
(substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT **Prostaglandins**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT Drug delivery systems
(suspensions, **ophthalmic**; substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT Adrenoceptor agonists
(α2-; substituted 5-hydroxyindole compds. for treatment of **glaucoma**)

IT Adrenoceptor antagonists
(β-; substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT 548797-06-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT 9003-39-8, Polyvinylpyrrolidone **9004-62-0**, Hydroxyethyl cellulose **9004-65-3**, Hydroxypropyl methyl cellulose **9004-67-5**, Methyl cellulose **37353-59-6**, Hydroxymethyl cellulose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
IT **9004-62-0**, Hydroxyethyl cellulose **9004-65-3**, Hydroxypropyl methyl cellulose **9004-67-5**, Methyl cellulose **37353-59-6**, Hydroxymethyl cellulose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted 5-hydroxyindole compds. for treatment of **glaucoma**)
RN 9004-62-0 HCAPLUS
CN Cellulose, 2-hydroxyethyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 107-21-1
CMF C2 H6 O2



RN 9004-65-3 HCAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2

RN 9004-67-5 HCAPLUS
CN Cellulose, methyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



RN 37353-59-6 HCAPLUS
CN Cellulose, hydroxymethyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 463-57-0
CMF C H4 O2

L116 ANSWER 9 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:754995 HCAPLUS
DN 137:268473
ED Entered STN: 04 Oct 2002
TI Porous drug matrices and methods of manufacture thereof
IN Straub, Julie; Altreuter, David; Bernstein, Howard; Chickering, Donald E.;

Khattak, Sarwat; Randall, Greg
PA Acusphere Inc., USA
SO U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U. S. 6,395,300.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K009-14
ICS A61K009-50
NCL 424499000
CC 63-6 (Pharmaceuticals)
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002142050	A1	20021003	US 2002-53929	20020122 <--
US 6395300	B1	20020528	US 1999-433486	19991104 <--
US 6645528	B1	20031111	US 2000-694407	20001023 <--
ZA 2001010347	A	20030730	ZA 2001-10347	20011218 <--
PRAI US 1999-136323P	P	19990527 <--		
US 1999-158659P	P	19991008 <--		
US 1999-433486	A2	19991104 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002142050	ICM	A61K009-14
	ICS	A61K009-50
	NCL	424499000
US 2002142050	ECLA	A61K009/16P4; A61K009/16P2 <--
US 6395300	ECLA	A61K009/16P4; A61K009/16P2 <--
US 6645528	ECLA	A61K009/16H2; A61K009/16H6B; A61K009/16H4B; A61K009/16P4; A61K009/16P2 <--

AB Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissoln. of the drug in aqueous media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. Thus, 5.46 g of PEG 8000, 0.545 g of prednisone, and 0.055 g of Span 40 were dissolved in 182 mL of methylene chloride. A solution of 3.27 g of ammonium bicarbonate in 18.2 mL of water was added to the organic solution (phase ratio 1:10) and homogenized for 5 min at 16,000 RPM. The resulting emulsion was spray dried on a benchtop spray dryer using an air-atomizing nozzle and nitrogen as the drying gas.

ST porous drug matrix microparticle prednisone bicarbonate
IT Drug delivery systems
(buccal; porous drug matrixes and methods of manufacture thereof)

IT Estrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated; porous drug matrixes and methods of manufacture thereof)
IT Drying
(fluid bed; porous drug matrixes and methods of manufacture thereof)
IT Drug delivery systems
(inhalants; porous drug matrixes and methods of manufacture thereof)
IT Drug delivery systems
(injections, i.m.; porous drug matrixes and methods of manufacture thereof)
IT Drug delivery systems
(injections, i.v.; porous drug matrixes and methods of manufacture thereof)
IT Drug delivery systems
(injections, s.c.; porous drug matrixes and methods of manufacture thereof)
IT Drug delivery systems
(microparticles; porous drug matrixes and methods of manufacture thereof)
IT Drug delivery systems
(nasal; porous drug matrixes and methods of manufacture thereof)
IT Drug delivery systems
(**ophthalmic**; porous drug matrixes and methods of manufacture thereof)
IT Drug delivery systems
(oral; porous drug matrixes and methods of manufacture thereof)
IT Drug delivery systems
(parenterals; porous drug matrixes and methods of manufacture thereof)
IT Dissolution
Freeze drying
Preservatives
Solvents
(porous drug matrixes and methods of manufacture thereof)
IT Amino acids, biological studies
Carbohydrates, biological studies
Granulocyte colony-stimulating factor receptors
Interferons
Interleukins
Lecithins
Polymers, biological studies
Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(porous drug matrixes and methods of manufacture thereof)
IT Crystallization
(prevention of; porous drug matrixes and methods of manufacture thereof)
IT Drug delivery systems
(rectal; porous drug matrixes and methods of manufacture thereof)
IT Drug delivery systems
(sublingual; porous drug matrixes and methods of manufacture thereof)
IT Drying
(vacuum; porous drug matrixes and methods of manufacture thereof)
IT Drug delivery systems
(vaginal; porous drug matrixes and methods of manufacture thereof)
IT 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide 52-53-9, Verapamil 53-03-2, Prednisone 55-98-1, Busulfan 57-63-6, Ethinyl estradiol 58-61-7, Adenosine, biological studies 59-92-7, Levodopa, biological studies 67-78-7 67-97-0, Vitamin D3 71-58-9, Medroxyprogesterone acetate 75-64-9, Erbumine, biological studies 77-36-1, Chlorthalidone 89-57-6, Mesalamine 126-07-8, Griseofulvin 128-13-2, Ursodiol 298-46-4, Carbamazepine 302-79-4, Tretinoin 321-64-2, Tacrine **363-24-6**, Dinoprostone 437-38-7, Fentanyl 439-14-5, Diazepam 443-48-1, Metronidazole 518-28-5, Podofilox 631-61-8, Ammonium acetate 657-24-9, Metformin **745-65-3**, Alprostadil 846-49-1, Lorazepam 1066-33-7, Ammonium bicarbonate 1863-63-4, Ammonium benzoate 1951-25-3, Amiodarone 3239-44-9, Dexfenfluramine 4759-48-2, Isotretinoin 5534-09-8, Beclomethasone dipropionate 5593-20-4, Betamethasone dipropionate 9002-68-0,

Follitropin 9002-72-6, Growth hormone **9005-65-6**, Tween 80
9007-12-9, Calcitonin 9041-93-4, Bleomycin sulfate 10238-21-8,
Glyburide 11096-26-7, Erythropoietin 12125-02-9, Ammonium chloride,
biological studies 12629-01-5, Somatropin 12633-72-6, Amphotericin
13311-84-7, Flutamide 15307-79-6, Diclofenac sodium 15307-86-5,
Diclofenac 15687-27-1, Ibuprofen 18559-94-9, Albuterol 20830-75-5,
Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22204-53-1,
Naproxen 25322-68-3, Polyethylene glycol 26266-57-9, Span 40
27203-92-5, Tramadol 28860-95-9, Carbidopa 28981-97-7, Alprazolam.
29094-61-9, Glipizide 30516-87-1, Zidovudine 32986-56-4, Tobramycin
33069-62-4, Paclitaxel 34911-55-2, Bupropion 36505-84-7, Buspirone
40391-99-9 41340-25-4, Etodolac 41575-94-4, Carboplatin 42399-41-7,
Diltiazem 42924-53-8, Nabumetone 51333-22-3, Budesonide 51773-92-3,
Mefloquine hydrochloride 54143-55-4, Flecainide 54527-84-3,
Nicardipine hydrochloride 54910-89-3, Fluoxetine 54965-21-8,
Albendazole 54965-24-1, Tamoxifen citrate 55268-75-2, Cefuroxime
56124-62-0, Valrubicin 56180-94-0, Acarbose 60142-96-3, Gabapentin
60205-81-4, Ipratropium. 63659-18-7, Betaxolol 65277-42-1,
Ketoconazole 66085-59-4, Nimodipine 66376-36-1, Alendronate
66852-54-8, Halobetasol propionate 68693-11-8, Modafinil 69655-05-6,
Didanosine 70476-82-3, Mitoxantrone hydrochloride 72432-03-2, Miglitol
72509-76-3, Felodipine 72558-82-8, Ceftazidime 72956-09-3, Carvedilol
73384-59-5, Ceftriaxone 73590-58-6, Omeprazole 75330-75-5, Lovastatin
75695-93-1, Isradipine 75847-73-3, Enalapril 76095-16-4, Enalapril
maleate 76547-98-3, Lisinopril 76824-35-6, Famotidine 76963-41-2,
Nizatidine 77883-43-3, Doxazosin mesylate 78246-49-8, Paroxetine
hydrochloride 78628-80-5, Terbinafine hydrochloride 78755-81-4,
Flumazenil 79517-01-4, Octreotide acetate 79559-97-0, Sertraline
hydrochloride 79794-75-5, Loratadine 79902-63-9, Simvastatin
80274-67-5, Metoprolol fumarate 81098-60-4, Cisapride 81103-11-9,
Clarithromycin 82410-32-0, Ganciclovir 82752-99-6, Nefazodone
hydrochloride 82834-16-0, Perindopril 83799-24-0, Fexofenadine
83905-01-5, Azithromycin 83919-23-7, Mometasone furoate 84625-61-6,
Itraconazole 86386-73-4, Fluconazole 86541-74-4, Benazepril
hydrochloride 86541-75-5, Benazepril 87679-37-6, Trandolapril
89778-27-8, Toremifene citrate 90566-53-3, Fluticasone 91161-71-6,
Terbinafine 91421-42-0, Rubitecan 93413-69-5, Venlafaxine
93957-54-1, Fluvastatin 95058-81-4, Gemcitabine 95233-18-4, Atovaquone
97048-13-0, Urofollitropin 97322-87-7, Troglitazone 98048-97-6,
Fosinopril 98079-52-8, Lomefloxacin hydrochloride 98319-26-7,
Finasteride 99011-02-6, Imiquimod 99294-93-6, Zolpidem tartrate
100286-90-6, Irinotecan hydrochloride 100986-85-4, Levofloxacin
103577-45-3, Lansoprazole 103628-48-4, Sumatriptan succinate
103775-10-6, Moexipril 104227-87-4, Famciclovir 104632-25-9,
Pramipexole dihydrochloride 106266-06-2, Risperidone 106392-12-5,
Pluronic f127 106463-17-6, Tamsulosin hydrochloride 106685-40-9,
Adapalene 107753-78-6, Zafirlukast 109889-09-0, Granisetron
110871-86-8, Sparfloxacin 111470-99-6, Amlodipine besylate
111974-72-2, Quetiapine fumarate 112809-51-5, Letrozole 113806-05-6,
Olopatadine 114798-26-4, Losartan 114977-28-5, Docetaxel
115956-12-2, Dolasetron 120014-06-4, Donepezil 124832-26-4,
Valacyclovir 127779-20-8, Saquinavir 131918-61-1, Paricalcitol
132539-06-1, Olanzapine 134308-13-7, Tolcapone 134678-17-4, Lamivudine
137862-53-4, Valsartan 140678-14-4, Mangafodipir trisodium
142373-60-2, Tirofiban hydrochloride 144701-48-4, Telmisartan
145040-37-5, Candesartan cilexetil 147059-72-1, Trovafloxacin
147245-92-9, Glatiramer acetate 150378-17-9, Indinavir 154248-97-2,
Imiglucerase 154598-52-4, Efavirenz 155141-29-0, Rosiglitazone maleate
155213-67-5, Ritonavir 158966-92-8, Montelukast 159989-65-8,
Nelfinavir mesylate 161814-49-9, Amprenavir 162011-90-7, Rofecoxib
169590-42-5, Celecoxib 171599-83-0, Sildenafil citrate 260779-88-2,
Cisapride monohydrate 679809-58-6, Enoxaparin sodium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(porous drug matrixes and methods of manufacture thereof)
IT **363-24-6**, Dinoprostone **745-65-3**, Alprostadil
9005-65-6, Tween 80
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(porous drug matrixes and methods of manufacture thereof)
RN 363-24-6 HCAPLUS
CN Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-,
(5Z,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 745-65-3 HCAPLUS
CN Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11α,13E,15S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs.
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L116 ANSWER 10 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:368323 HCAPLUS
DN 136:363886
ED Entered STN: 18 May 2002
TI Improved treatment of glaucoma by **intraocular** pressure-reducing
agent combination
IN Richardson, Helene; Zimmerman, Thom J.; Challoner, Teresa; Jonsson, Per;
Groenbladh, Anna; Oehagen, Patrik; Gieseker, Donald
PA Pharmacia AB, Swed.
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-5575
ICS A61K031-535
CC 1-12 (Pharmacology)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002038158	A1	20020516	WO 2001-SE2499	20011112 <--
	WO 2002038158	C1	20030130		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003018079	A1	20030123	US 2001-35963	20011109 <--
	AU 2002015277	A5	20020521	AU 2002-15277	20011112 <--
	EP 1333837	A1	20030813	EP 2001-983882	20011112 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001015208	A	20031007	BR 2001-15208	20011112 <--
	JP 2004513148	T2	20040430	JP 2002-540741	20011112 <--
	NO 2003002122	A	20030701	NO 2003-2122	20030512 <--
PRAI	US 2000-248123P	P	20001113 <--		
	WO 2001-SE2499	W	20011112 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002038158	ICM	A61K031-5575
	ICS	A61K031-535
JP 2004513148	FTERM	4C084/AA20; 4C084/BA44; 4C084/CA59; 4C084/MA02; 4C084/MA58; 4C084/NA05; 4C084/NA14; 4C084/ZA212; 4C084/ZA332; 4C084/ZA392; 4C084/ZC022; 4C084/ZC202; 4C086/AA01; 4C086/AA02; 4C086/BC85; 4C086/DA02; 4C086/GA09; 4C086/GA10; 4C086/MA02; 4C086/MA17; 4C086/MA58; 4C086/NA05; 4C086/NA14; 4C086/ZA21; 4C086/ZA33; 4C086/ZA39; 4C086/ZC02; 4C086/ZC20 <--

AB The present invention is directed to using two or more agents in combination with capacity of reducing the **intraocular** pressure (IOP) in a therapy with an improved efficacy to treat advanced glaucoma in such patients who suffer from detectable vision related impairments, when said agents are administered simultaneously. The combined use will also find advantage in treatment of individuals in need of a high IOP-reduction, such as those being exposed to risk factors rendering them susceptible to visual impairments. A fixed combination of **latanoprost** (50 μg/mL) and timolol (5 mg/mL) showed an unexpected efficacy in patients suffering from both abnormalities of the optic nerve head and visual field defects when compared to patients having an elevated IOP but otherwise free from complications. **Eye** drop formulations are given.

ST glaucoma combination therapy; **intraocular** pressure reducing agent combination antiglaucoma; **latanoprost** timolol **eye** drop glaucoma treatment

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)

IT **Vision**
(disorder, field defects; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)

IT Antiglaucoma agents
Human
(improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)

IT Ischemia
(in region of optical nerve head; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
IT **Eye**
(**intraocular** pressure, reduction of; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
IT **Prostaglandins**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**intraocular** pressure-reducing; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
IT Drug delivery systems
(**ophthalmic**; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
IT **Eye, disease**
(optical nerve head damage; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
IT Drug delivery systems
(solns., **ophthalmic**; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
IT **Eye**
(uveosclera, agent increasing vitreous humor outflow from; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
IT **Eye**
(vitreous humor, agent increasing uveoscleral outflow of or reducing formation of; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
IT Adrenoceptor agonists
(β-; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
IT 26839-75-8, Timolol 26921-17-5, Timolol maleate **120373-24-2**, **Isopropyl unoprostone 130209-82-4**, **Latanoprost 157283-68-6**, Travoprost
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
IT 1310-73-2, Sodium hydroxide, biological studies 7558-79-4, Disodium phosphate 7558-80-7, Sodium dihydrogen phosphate 7647-01-0, Hydrochloric acid, biological studies 7647-14-5, Sodium chloride, biological studies 7732-18-5, Water, biological studies **9005-65-6**, Polysorbate 80
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
IT **551-11-1D**, Prostaglandin F2α, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**intraocular** pressure-reducing; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Kiyoshi, I; Jpn J Ophthalmol 2000, V44, P227
(2) Michael, D; Graefe's Arch Clin Exp Ophthalmol 1998, V236, P577
(3) Michael, D; Survey of Ophthalmology 1997, V41, PS77
(4) Peter, R; Arch Ophthalmol 1996, V114, P268
IT **120373-24-2**, **Isopropyl unoprostone**
130209-82-4, **Latanoprost 157283-68-6**,

Travoprost
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)

RN 120373-24-2 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 130209-82-4 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 157283-68-6 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



IT **9005-65-6**, Polysorbate 80
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **551-11-1D**, Prostaglandin F2α, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**intraocular** pressure-reducing; improved treatment of glaucoma by **intraocular** pressure-reducing agent combination)
RN 551-11-1 HCAPLUS
CN Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9α,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L116 ANSWER 11 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:220376 HCAPLUS
DN 136:252497
ED Entered STN: 22 Mar 2002
TI **Eye** drops containing prostaglandin derivatives and nonionic surfactants and/or antioxidants
IN Morishima, Kenji; Kimura, Akio; Asada, Hiroyuki; Umeda, Masayuki; Kuwano, Mitsuaki
PA Santen Pharmaceutical Co., Ltd., Japan; Asahi Glass Company, Ltd.
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM A61K031-5575
ICS A61K009-08; A61K047-34; A61K047-44; A61K047-18; A61K047-10; A61P027-02

CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022131	A1	20020321	WO 2001-JP7928	20010913 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001086210	A5	20020326	AU 2001-86210	20010913 <--
	JP 2002161037	A2	20020604	JP 2001-277356	20010913 <--
	EP 1321144	A1	20030625	EP 2001-965597	20010913 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NO 2003001138	A	20030512	NO 2003-1138	20030312 <--
	US 2004097592	A1	20040520	US 2003-380401	20030312 <--
PRAI	JP 2000-277554	A	20000913 <--		
	WO 2001-JP7928	W	20010913 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002022131	ICM	A61K031-5575
	ICS	A61K009-08; A61K047-34; A61K047-44; A61K047-18; A61K047-10; A61P027-02

AB It is intended to produce **eye** drop prepns. containing prostaglandin derivs. which are hardly soluble in water and liable to be adsorbed by resin containers or prostaglandin derivs. which are liable to decompose when dissolved in water. The solubility of prostaglandin derivs. in water can be improved and the adsorption thereof by resin containers can be remarkably inhibited by adding nonionic surfactants such as polysorbate 80 or polyoxyethylene-hardened castor oil 60 to **eye** drops. Moreover, the decomposition of prostaglandin derivs. can be remarkably inhibited by adding antioxidants such as disodium ethylenediaminetetraacetate or dibutylhydroxytoluene. The effect of addition of polysorbate 80 at 0.01 % in a solution containing 16-Phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2α iso-Pr ester 0.001 % in a polyethylene container on prevention of adsorption of the prostaglandin derivative to the container during storage was examined

ST prostaglandin deriv **ophthalmic** soln nonionic surfactant

IT Antioxidants
(**eye** drops containing prostaglandin derivs. and nonionic surfactants and/or antioxidants)

IT **Prostaglandins**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**eye** drops containing prostaglandin derivs. and nonionic surfactants and/or antioxidants)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**eye** drops containing prostaglandin derivs. and nonionic surfactants and/or antioxidants in resin containers)

IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated, ethoxylated; **eye** drops containing prostaglandin derivs. and nonionic surfactants and/or antioxidants)

IT Surfactants
(nonionic; **eye** drops containing prostaglandin derivs. and nonionic surfactants and/or antioxidants)

IT Drug delivery systems

(solns., **ophthalmic**; **eye** drops containing prostaglandin derivs. and nonionic surfactants and/or antioxidants)

IT 139-33-3, Disodium ethylenediaminetetraacetate **551-11-1D**, Prostaglandin F2α, derivs. **9005-65-6**, Polysorbate 80 30587-81-6, Dibutylhydroxytoluene **209860-87-7**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**eye** drops containing prostaglandin derivs. and nonionic surfactants and/or antioxidants)

IT 9002-88-4, Polyethylene 9003-07-0, Polypropylene 24968-11-4, Polyethylene naphthalate 25038-59-9, Polyethylene terephthalate, biological studies 25230-87-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**eye** drops containing prostaglandin derivs. and nonionic surfactants and/or antioxidants in resin containers)

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Alcon Laboratories Inc; JP 06316525 A 1994 HCAPLUS
(2) Alcon Laboratories Inc; CA 2112027 A 1994 HCAPLUS
(3) Alcon Laboratories Inc; US 5565492 A 1994 HCAPLUS
(4) Alcon Laboratories Inc; EP 603800 A 1994 HCAPLUS
(5) Alcon Laboratories Inc; AU 665287 B 1994 HCAPLUS
(6) Allergan Inc; JP 09506081 A 1996
(7) Allergan Inc; US 5486540 A 1996 HCAPLUS
(8) Allergan Inc; US 5486540 A 1996 HCAPLUS
(9) Allergan Inc; EP 725643 A 1996 HCAPLUS
(10) Allergan Inc; AU 9480844 A 1996
(11) Allergan Inc; WO 9511682 A 1996
(12) Santen Pharmaceutical Co Ltd; JP 11071344 A 1998 HCAPLUS
(13) Santen Pharmaceutical Co Ltd; CA 2225761 A 1998 HCAPLUS
(14) Santen Pharmaceutical Co Ltd; US 5886035 A 1998 HCAPLUS
(15) Santen Pharmaceutical Co Ltd; US 5985920 A 1998 HCAPLUS
(16) Santen Pharmaceutical Co Ltd; EP 850926 A 1998 HCAPLUS
(17) Santen Pharmaceutical Co Ltd; JP 10251225 A 1999 HCAPLUS
(18) Santen Pharmaceutical Co Ltd; EP 930296 A 1999 HCAPLUS

IT **551-11-1D**, Prostaglandin F2α, derivs. **9005-65-6**, Polysorbate 80 **209860-87-7**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**eye** drops containing prostaglandin derivs. and nonionic surfactants and/or antioxidants)

RN 551-11-1 HCAPLUS
CN Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5Z,9α,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 209860-87-7 HCAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-butenyl]-3,5-dihydroxycyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L116 ANSWER 12 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:122796 HCAPLUS
DN 136:172791
ED Entered STN: 15 Feb 2002
TI Aqueous pharmaceutical compositions having a low gelation temperature
IN Suzuki, Hidekazu; Wada, Takahiro; Kirita, Masanobu; Takeuchi, Masanobu
PA Wakamoto Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM A61K031-5383
ICS A61K009-08; A61K047-12; A61K047-34; A61K047-38; A61P031-04
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002011734	A1	20020214	WO 2001-JP6805	20010808 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2003160473	A2	20030603	JP 2000-240455	20000808 <--
	JP 3450805	B2	20030929		
	AU 2001078696	A5	20020218	AU 2001-78696	20010808 <--
	EP 1312366	A1	20030521	EP 2001-956809	20010808 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 3504656	B2	20040308	JP 2002-517070	20010808 <--
	NO 2003000533	A	20030226	NO 2003-533	20030203 <--
	US 2003194441	A1	20031016	US 2003-344189	20030602 <--
PRAI	JP 2000-240455	A	20000808 <--		
	WO 2001-JP6805	W	20010808 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES

WO 2002011734	ICM	A61K031-5383
	ICS	A61K009-08; A61K047-12; A61K047-34; A61K047-38; A61P031-04
EP 1312366	ECLA	A61K009/00M16; A61K031/5383 <--
US 2003194441	ECLA	A61K009/00M16; A61K031/5383; A61K047/00R <--

AB The invention aims at providing an antimicrobial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when contain new quinolone antimicrobial agents such as ofloxacin as the active ingredient and can stay at the site of administration for a long time by virtue of rapid **viscosity** increase after administration in spite of their being liquid at administration and thereby attain high availability. The invention relates to an antimicrobial aqueous pharmaceutical composition containing 2.8 to 4 % weight/volume of Me cellulose, 2 weight/volume aqueous solution of which has a **viscosity** of 12mPa s or below at 20°, 1.5 to 2.3 % weight/volume of citric acid, 2 to 4 % weight/volume of polyethylene glycol, and 0.1 to 0.5 % weight/volume of ofloxacin.

ST pharmaceutical soln gelation cellulose citrate PEG; ofloxacin soln thermal gelation

IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aqueous pharmaceutical compns. with low gelation temperature)

IT Drug delivery systems
(solns., **ophthalmic**; aqueous pharmaceutical compns. with low gelation temperature)

IT Drug delivery systems
(solns.; aqueous pharmaceutical compns. with low gelation temperature)

IT Gelation
(thermal; aqueous pharmaceutical compns. with low gelation temperature)

IT 50-21-5, Lactic acid, biological studies 52-21-1, Prednisolone acetate 54-71-7, Pilocarpine hydrochloride 56-84-8, Asparaginic acid, biological studies 61-76-7, Phenylephrine hydrochloride 72-17-3, Sodium lactate 77-92-9, Citric acid, biological studies 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 151-73-5, Betamethasone sodium phosphate 426-13-1, Fluorometholone 518-47-8, Sodium fluorescein 526-95-4, Gluconic acid 527-07-1, Sodium gluconate 1043-21-6, Pirenoxine 1405-41-0, Gentamicin sulfate 1508-75-4, Tropicamide 7704-73-6, Sodium fumarate **9004-67-5**, Methyl cellulose 14475-11-7, Sodium tartrate 15307-79-6, Diclofenac sodium 15826-37-6, Sodium cromoglycate 16177-21-2, Sodium L-glutamate 18016-19-8, Sodium maleate 25322-68-3, Polyethylene glycol 26921-17-5, Timolol maleate 34580-14-8, Ketotifen fumarate 51781-21-6, Carteolol hydrochloride 52549-17-4, Pranoprofen 53902-12-8, Tranilast 59277-89-3, Acyclovir 59865-13-3, Cyclosporin A 63659-19-8, Betaxolol hydrochloride 81486-22-8, Nipradilol 82419-36-1, Ofloxacin 91714-93-1, Bromfenac sodium 100986-85-4, Levofloxacin 114607-46-4, Acitazanolast **120373-24-2**, **Isopropylunoprostone** 186826-86-8, Moxifloxacin hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aqueous pharmaceutical compns. with low gelation temperature)

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Asta Pharma Ag; JP 01153639 A 1992 HCAPLUS
(2) Asta Pharma Ag; JP 10182464 A 1992 HCAPLUS
(3) Asta Pharma Ag; JP 11349484 A 1992 HCAPLUS
(4) Asta Pharma Ag; CA 1319322 A1 1992 HCAPLUS
(5) Asta Pharma Ag; ES 2053678 T3 1992 HCAPLUS
(6) Asta Pharma Ag; JP 2911460 B 1992 HCAPLUS
(7) Asta Pharma Ag; JP 2956029 B 1992 HCAPLUS

(8) Asta Pharma Ag; EP 316633 A1 1992 HCAPLUS
(9) Asta Pharma Ag; EP 316633 B1 1992 HCAPLUS
(10) Asta Pharma Ag; JP 3207816 B 1992 HCAPLUS
(11) Asta Pharma Ag; DE 3836579 A1 1992 HCAPLUS
(12) Asta Pharma Ag; US 5164194 A 1992 HCAPLUS
(13) Asta Pharma Ag; AU 613107 B2 1992 HCAPLUS
(14) Asta Pharma Ag; AT 84968 E 1992 HCAPLUS
(15) Asta Pharma Ag; DK 8806301 A 1992 HCAPLUS
(16) Asta Pharma Ag; ZA 8808461 A 1992 HCAPLUS
(17) Asta Pharma Ag; AU 8825063 A1 1992 HCAPLUS
(18) Shin-Etsu Chemical Company Ltd; JP 2000001443 A 1999 HCAPLUS
(19) Shin-Etsu Chemical Company Ltd; US 6171616 B1 1999 HCAPLUS
(20) Shin-Etsu Chemical Company Ltd; EP 950419 A1 1999 HCAPLUS
(21) Wakamoto Pharmaceutical Co Ltd; CN 1048393 B 1996
(22) Wakamoto Pharmaceutical Co Ltd; IL 107626 A1 1996 HCAPLUS
(23) Wakamoto Pharmaceutical Co Ltd; CN 1097593 A 1996 HCAPLUS
(24) Wakamoto Pharmaceutical Co Ltd; IL 111299 A1 1996 HCAPLUS
(25) Wakamoto Pharmaceutical Co Ltd; AT 189772 E 1996 HCAPLUS
(26) Wakamoto Pharmaceutical Co Ltd; RU 2108112 C1 1996 HCAPLUS
(27) Wakamoto Pharmaceutical Co Ltd; ES 2141775 T3 1996 HCAPLUS
(28) Wakamoto Pharmaceutical Co Ltd; CA 2153234 A 1996 HCAPLUS
(29) Wakamoto Pharmaceutical Co Ltd; JP 2729859 B 1996 HCAPLUS
(30) Wakamoto Pharmaceutical Co Ltd; US 5624962 A 1996 HCAPLUS
(31) Wakamoto Pharmaceutical Co Ltd; AU 668447 B2 1996 HCAPLUS
(32) Wakamoto Pharmaceutical Co Ltd; EP 694310 A1 1996 HCAPLUS
(33) Wakamoto Pharmaceutical Co Ltd; EP 694310 B1 1996 HCAPLUS
(34) Wakamoto Pharmaceutical Co Ltd; HU 71676 A2 1996 HCAPLUS
(35) Wakamoto Pharmaceutical Co Ltd; WO 9423750 A1 1996 HCAPLUS
(36) Wakamoto Pharmaceutical Co Ltd; AU 9454333 A1 1996 HCAPLUS
(37) Wakamoto Pharmaceutical Co Ltd; NO 9503189 A 1996 HCAPLUS
(38) Wakamoto Pharmaceutical Co Ltd; FI 9503575 A 1996 HCAPLUS
(39) Wakamoto Pharmaceutical Co Ltd; CN 1164185 A 1997 HCAPLUS
(40) Wakamoto Pharmaceutical Co Ltd; CA 2202520 A 1997 HCAPLUS
(41) Wakamoto Pharmaceutical Co Ltd; US 5756552 A 1997 HCAPLUS
(42) Wakamoto Pharmaceutical Co Ltd; AU 684558 B2 1997 HCAPLUS
(43) Wakamoto Pharmaceutical Co Ltd; EP 782850 A1 1997 HCAPLUS
(44) Wakamoto Pharmaceutical Co Ltd; AU 9478629 A1 1997 HCAPLUS
(45) Wakamoto Pharmaceutical Co Ltd; WO 9611672 A1 1997 HCAPLUS
(46) Wakamoto Pharmaceutical Co Ltd; FI 9701533 A 1997 HCAPLUS
(47) Wakamoto Pharmaceutical Co Ltd; NO 9701683 A 1997 HCAPLUS
(48) Wakamoto Pharmaceutics Co Ltd; WO 9830221 A1 1998 HCAPLUS
(49) Wakamoto Pharmaceutics Co Ltd; AU 9853424 A1 1998 HCAPLUS
(50) Wakamoto Pharmaceutics Co Ltd; JP 200148807 A 2001
IT **9004-67-5**, Methyl cellulose **120373-24-2**, **Isopropylunoprostone**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aqueous pharmaceutical compns. with low gelation temperature)
RN 9004-67-5 HCAPLUS
CN Cellulose, methyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

H_3C-OH

RN 120373-24-2 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L116 ANSWER 13 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:11105 HCAPLUS
DN 136:90949
ED Entered STN: 04 Jan 2002
TI Compositions containing **isopropyl unoprostone** for reducing **ocular** hypertension
IN Reed, Kenneth Warren; Yen, Shau Fong; Sou, Mary; Peacock, Regina Flinn
PA Novartis AG, USA
SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 42,817, abandoned.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-445
NCL 514330000
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002002185	A1	20020103	US 2001-812162	20010319 <--
	US 6770675	B2	20040803		
PRAI	US 1997-93065P	P	19970317 <--		
	US 1998-42817	B2	19980317 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002002185	ICM	A61K031-445
	NCL	514330000

GI



I

AB An improved **ophthalmic** composition, includes docosanoid active agents, which are especially useful in lowering **intraocular** pressure associated with glaucoma. Improvements in IOP reduction efficacy, preservative efficacy and reduced additive concns. are achieved by utilizing the disclosed compns. which include a docosanoid active agent (e.g., iso-Pr **unoprostone**, I), in conjunction with selected nonionic surfactants, preservatives, and nonionic tonicity adjusting agents.

ST **ocular** hypertension compn docosanoid; glaucoma **isopropyl unoprostone** compn

IT Quaternary ammonium compounds, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; compns. containing iso-Pr **unoprostone** for reducing **ocular** hypertension)

IT Antiglaucoma agents
Buffers
Chelating agents
Preservatives
(compns. containing iso-Pr **unoprostone** for reducing **ocular** hypertension)

IT Polyoxyalkylenes, biological studies
Quaternary ammonium compounds, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing iso-Pr **unoprostone** for reducing **ocular** hypertension)

IT Surfactants
(nonionic; compns. containing iso-Pr **unoprostone** for reducing **ocular** hypertension)

IT Fatty acids, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sodium salts; compns. containing iso-Pr **unoprostone** for reducing **ocular** hypertension)

IT Drug delivery systems
(solns., **ophthalmic**; compns. containing iso-Pr **unoprostone** for reducing **ocular** hypertension)

IT 11129-12-7, Borate 14265-44-2, Phosphate, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(buffer; compns. containing iso-Pr **unoprostone** for reducing **ocular** hypertension)

IT 50-70-4, Sorbitol, biological studies 54-64-8, Thimerosal 55-56-1, Chlorhexidine **56-81-5**, Glycerol, biological studies 57-09-0, Cetyltrimethylammonium bromide 57-15-8, Chlorobutanol 59-50-7, 3-Methyl-4-chlorophenol 60-00-4, Edta, biological studies 60-12-8, 2-Phenylethanol 69-65-8, D-Mannitol 80-46-6, 4-tert-Amylphenol 90-43-7, 2-Phenylphenol 95-56-7D, o-Bromophenol, alkyl derivs. 95-57-8D, o-Chlorophenol, alkyl derivs. 97-23-4 98-54-4, 4-tert-Butylphenol 100-51-6, Benzenemethanol, biological studies 106-41-2D, p-Bromophenol, alkyl derivs. 106-48-9D, p-Chlorophenol, alkyl derivs. 112-80-1D, Oleic acid, sulfonated, sodium salts 117-80-6,

2,3-Dichloro-1,4-naphthoquinone 120-32-1, 2-Benzyl-4-chlorophenol 121-54-0, Benzethonium chloride 122-99-6, 2-Phenoxyethanol 123-03-5, Cetylpyridinium chloride 148-24-3, 8-Quinolinol, biological studies 1321-23-9, Chloroxylenol 1331-61-9, Benzenesulfonic acid, dodecyl-, ammonium salt 2027-47-6D, 9-Octadecenoic acid, sulfonated 3772-94-9, Pentachlorophenyl laurate 5324-84-5, Sodium 1-octanesulfonate 5964-24-9, Thimerfonate sodium 9004-98-2, Brij 97 **9005-63-4D**, Polyoxyethylene sorbitan, ratty acid **esters 9005-65-6**, Polysorbate 80 13081-16-8, 4-Chloro-2-pentylphenol 13347-42-7, 2-Cyclopentyl-4-chlorophenol 19379-90-9, Benzoxonium chloride 25155-19-5, Naphthalenesulfonic acid 25155-30-0 25322-68-3, Peg 25322-69-4, Polypropylene glycol 27177-77-1, Benzenesulfonic acid, dodecyl-, potassium salt 28757-47-3 30260-72-1 85721-33-1, Ciprofloxacin
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing **iso-Pr unoprostone** for reducing **ocular** hypertension)

IT **120373-24-2**, **Isopropyl unoprostone**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing iso-Pr **unoprostone** for reducing **ocular** hypertension)

IT **56-81-5**, Glycerol, biological studies **9005-63-4D**, Polyoxyethylene sorbitan, ratty acid **esters 9005-65-6**, Polysorbate 80
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing **iso-Pr unoprostone** for reducing **ocular** hypertension)

RN 56-81-5 HCAPLUS
CN 1,2,3-Propanetriol (9CI) (CA INDEX NAME)



RN 9005-63-4 HCAPLUS
CN Sorbitan, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **120373-24-2**, **Isopropyl unoprostone**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing iso-Pr **unoprostone** for reducing **ocular** hypertension)

RN 120373-24-2 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L116 ANSWER 14 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:392607 HCAPLUS
DN 136:144916
ED Entered STN: 31 May 2001
TI Effects of **isopropyl unoprostone ophthalmic** solution on cultured rabbit corneal epithelial cells
AU Wang, You-Dong; Kashiwagi, Kenji; Chen, Hai-Bo; Jin, Ming; Ou, Bo; Iizuka, Yoko; Tanaka, Yuko; Tsukahara, Shigeo
CS Department of Ophthalmology, Yamanashi Medical University, Yamanashi, 409-3898, Japan
SO Ophthalmologica (**2001**), 215(3), 229-234
CODEN: OPHTAD; ISSN: 0030-3755
PB S. Karger AG
DT Journal
LA English
CC 1-8 (Pharmacology)
AB Purpose: To investigate the effects of iso-Pr **unoprostone** (referred to as **unoprostone**) **ophthalmic** solution on the barrier function of cultured rabbit corneal epithelium grown on permeable supports. Methods: Rabbit corneal epithelial cells cultured on collagen-coated filter inserts were administered one of the following for 30 min: **unoprostone** in vehicle solution (polysorbate 80), **unoprostone** in vehicle solution with a preservative (benzalkonium chloride), preservative only, or vehicle only. For a control, no chems. were added to the medium. After administration, the transepithelial elec. resistance (TER) measurement, a sensitive method by which to investigate the barrier function, and morphol. observation using phase-contrast microscopy were performed before exposure and at 0.5, 1, 3, 6, 12, 24, 48, and 72 h after exposure. The transmission electron-microscopic observation was performed before and 72 h after exposure in all exptl. conditions. Results: The cells exposed to **unoprostone** with the preservative showed a significant decrease in the TER, although no morphol. changes were observed The corneal epithelial cells exposed to **unoprostone** without preservative, the vehicle only, or the preservative only did not show any differences from the control group at any measurements. Conclusion: The corneal barrier function is damaged by a combined solution of **unoprostone** and preservative, but not by a single solution of **unoprostone**, in vitro.
ST **isopropyl unoprostone ophthalmic** soln cornea epithelium
IT Quaternary ammonium compounds, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(alkylbenzyldimethyl, chlorides; effects of iso-Pr **unoprostone ophthalmic** solution on cultured rabbit corneal epithelial cells)
IT **Eye**
(cornea, epithelium; effects of iso-Pr **unoprostone ophthalmic** solution on cultured rabbit corneal epithelial cells)
IT **9005-65-6**, Polysorbate 80

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(effects of iso-Pr **unoprostone ophthalmic** solution on cultured rabbit corneal epithelial cells)

IT **120373-24-2**, **Isopropyl unoprostone**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(effects of iso-Pr **unoprostone ophthalmic** solution on cultured rabbit corneal epithelial cells)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Azuma, I; Jpn J Ophthalmol 1993, V37, P514 MEDLINE
(2) Azuma, I; Nippon Ganka Gakai Zasshi 1993, V97, P232 MEDLINE
(3) Geroski, D; Curr Eye Res 1992, V11, P61 MEDLINE
(4) Kashiwagi, K; Jpn J Pharmacol 1999, V81, P56 HCAPLUS
(5) Kawazu, K; Curr Eye Res 1998, V17, P125 MEDLINE
(6) Klyce, S; Curr Eye Res 1985, V4, P323 HCAPLUS
(7) Klyce, S; Structure and Function of the Cornea 1988, P3
(8) Komuro, A; Atarashii Ganka (Journal of the Eye) 1996, V13, P442
(9) Mishima, S; Invest Ophthalmol Vis Sci 1981, V21, P504 HCAPLUS
(10) Mishler, D; Am J Physiol 1990, V258, PF1561 HCAPLUS
(11) Motegi, Y; Folia Ophthalmol Jpn 1993, V44, P12
(12) Rosenberg, S; Am J Physiol 1991, V260, PC868 HCAPLUS
(13) Sakamoto, Y; Rinsho Ganka (Jpn J Clin Ophthalmol) 1995, V49, P1845
(14) Siegel, I; Exp Molec Pathol 1986, V44, P132 HCAPLUS
(15) Stevenson, B; J Cell Sci 1994, V107, P367 HCAPLUS
(16) Strissel, K; Invest Ophthalmol Vis Sci 1995, V36, P151 MEDLINE
(17) Sugahara, K; Am Rev Respir Dis 1986, V133, P875 HCAPLUS
(18) Takase, M; Nippon Ganka Gakkai Zasshi 1992, V96, P1261 MEDLINE
(19) Tonjum, A; Acta Ophthalmol 1975, V53, P358 MEDLINE
(20) Truschel, S; J Biol Chem 1999, V274, P15020 HCAPLUS
(21) Ueno, R; Acta Soc Ophthalmol Jpn 1992, V96, P462 HCAPLUS
(22) Williams, A; Introduction to Chemistry 1974, P391
(23) Wolosin, J; J Membr Biol 1988, V104, P45 HCAPLUS
(24) Yamamoto, T; Surv Ophthalmol 1997, V41, PS99

IT **9005-65-6**, Polysorbate 80
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(effects of iso-Pr **unoprostone ophthalmic** solution on cultured rabbit corneal epithelial cells)

RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **120373-24-2**, **Isopropyl unoprostone**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(effects of iso-Pr **unoprostone ophthalmic** solution on cultured rabbit corneal epithelial cells)

RN 120373-24-2 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L116 ANSWER 15 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN **2001:152470** HCAPLUS
DN **134:198100**
ED Entered STN: 02 Mar 2001
TI Oral liquid pharmaceuticals containing plasticizers and solubilizers
IN Wilson, Edward S.; Trespidi, Laura A.; Clark, Christy M.; Desai, Ashok J.; Meyer, Glenn A.; Sancilio, Frederick D.
PA Applied Analytical Industries, Inc., USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-48
ICS A61K009-52; A61K009-64; A61K009-66
CC 63-6 (Pharmaceuticals)
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001013897	A1	20010301	WO 2000-US19372	20000714 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6365180	B1	20020402	US 1999-354982	19990716 <--
	BR 2000012488	A	20020402	BR 2000-12488	20000714 <--
	EP 1196147	A1	20020417	EP 2000-948703	20000714 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	SI 20849	C	20021031	SI 2000-20031	20000714 <--
	JP 2003507415	T2	20030225	JP 2001-518035	20000714 <--
	AU 770772	B2	20040304	AU 2000-62168	20000714 <--
	NO 2002000208	A	20020318	NO 2002-208	20020115 <--
PRAI	US 1999-354982	A	19990716 <--		
	US 1998-71865P	P	19980120 <--		
	US 1999-232354	A2	19990115 <--		
	WO 2000-US19372	W	20000714 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001013897	ICM	A61K009-48
	ICS	A61K009-52; A61K009-64; A61K009-66

AB The present invention relates to novel, liquid and semi-solid pharmaceutical compns. which can be administered in a liquid form or can be used for preparing

capsules containing such pharmaceutical compns. Also provided are methods of using and processes for preparing the pharmaceutical compns. of the present invention. Thus, a composition contained gemfibrozil 15.0, PEG-400 54.5, water 2.5, glycerin 10.0, Polysorbate-80 3.0, and PVP K29-32 15.0% by weight

ST oral liq pharmaceutical plasticizer solubilizer

IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C1-4; oral liquid pharmaceuticals containing plasticizers and solubilizers)

IT Carboxylic acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aromatic; oral liquid pharmaceuticals containing plasticizers and solubilizers)

IT Carboxylic acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arylalkyl; oral liquid pharmaceuticals containing plasticizers and solubilizers)

IT Drug delivery systems
(capsules; oral liquid pharmaceuticals containing plasticizers and solubilizers)

IT Gastrointestinal motility
(gastric; oral liquid pharmaceuticals containing plasticizers and solubilizers)

IT Drug delivery systems
(liqs., oral; oral liquid pharmaceuticals containing plasticizers and solubilizers)

IT Anti-inflammatory agents
(nonsteroidal; oral liquid pharmaceuticals containing plasticizers and solubilizers)

IT Antihistamines
Plasticizers
Solubilizers
Stabilizing agents
Surfactants
(oral liquid pharmaceuticals containing plasticizers and solubilizers)

IT Carbohydrates, biological studies
Gelatins, biological studies
Polymers, biological studies
Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral liquid pharmaceuticals containing plasticizers and solubilizers)

IT Drug delivery systems
(semisolid; oral liquid pharmaceuticals containing plasticizers and solubilizers)

IT **Lactams**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β -; oral liquid pharmaceuticals containing plasticizers and solubilizers)

IT 50-70-4, Sorbitol, biological studies 53-86-1, Indomethacin **56-81-5**, Glycerin, biological studies 57-55-6, Propylene glycol, biological studies 57-66-9, Probenecid 59-92-7, Levodopa, biological studies 61-33-6, biological studies 61-68-7, Mefenamic acid 69-53-4, Ampicillin 99-66-1, Valproic acid 302-79-4, Retinoic acid 364-62-5, Metoclopramide 530-78-9, Flufenamic acid 644-62-2, Meclofenamic acid-5104-49-4, Flurbiprofen 6893-02-3, Liothyronine 9003-39-8, PVP **9004-64-2**, Hydroxypropyl cellulose **9004-65-3**, HPMC **9005-65-6**, Tween-80 11111-12-9, Cephalosporin 12619-70-4, Cyclodextrin 15307-79-6, Diclofenac sodium 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 15826-37-6, Cromolyn sodium 16110-51-3, Cromolyn 22071-15-4, Ketoprofen 22204-53-1, Naproxen 22494-42-4, Diflunisal 25322-68-3, Polyethylene glycol 25812-30-0, Gemfibrozil 26171-23-3, Tolmetin 26787-78-0, Amoxicillin 28860-95-9, Carbidopa 29679-58-1, Fenoprofen **35700-23-3**, Carboprost 38194-50-2, Sulindac 41340-25-4, Etodolac 52214-84-3, Ciprofibrate 73590-58-6, Omeprazole

74103-06-3, Ketorolac 75330-75-5, Lovastatin 79902-63-9, Simvastatin
81093-37-0, Pravastatin 82419-36-1, Ofloxacin 83799-24-0, Fexofenadine
85441-61-8, Quinapril 85721-33-1, Ciprofloxacin 93957-54-1,
Fluvastatin 98079-51-7, Lomefloxacin 134523-00-5, Atorvastatin
145599-86-6, Cerivastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral liquid pharmaceuticals containing plasticizers and solubilizers)
IT 9000-83-3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proton-translocating, inhibitors; oral liquid pharmaceuticals containing
plasticizers and solubilizers)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Caldwell; US 5183829 A 1993 HCAPLUS
(2) Frisbee; US 6013280 A 2000 HCAPLUS
(3) Shelley; US 5505961 A 1996 HCAPLUS
IT **56-81-5**, Glycerin, biological studies **9004-64-2**,
Hydroxypropyl cellulose **9004-65-3**, HPMC **9005-65-6**,
Tween-80 **35700-23-3**, Carboprost
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral liquid pharmaceuticals containing plasticizers and solubilizers)
RN 56-81-5 HCAPLUS
CN 1,2,3-Propanetriol (9CI) (CA INDEX NAME)



RN 9004-64-2 HCAPLUS
CN Cellulose, 2-hydroxypropyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9004-65-3 HCAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

H_3C-OH

CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 35700-23-3 HCAPLUS
CN Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9α,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L116 ANSWER 16 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:861473 HCAPLUS
DN 134:32972
ED Entered STN: 08 Dec 2000
TI Porous drug matrixes containing polymers and sugars and methods of their manufacture
IN Straub, Julie; Bernstein, Howard; Chickering, Donald E., III; Khatak, Sarwat; Randall, Greg
PA Acusphere, Inc., USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-16
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2000072827 A2 20001207 WO 2000-US14578 20000525 <--
WO 2000072827 A3 20010125
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 6395300 B1 20020528 US 1999-433486 19991104 <--
EP 1180020 A2 20020220 EP 2000-939365 20000525 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
BR 2000010984 A 20020430 BR 2000-10984 20000525 <--
JP 2003500438 T2 20030107 JP 2000-620939 20000525 <--
NZ 516083 A 20030829 NZ 2000-516083 20000525 <--
AU 768022 B2 20031127 AU 2000-54459 20000525 <--
US 2002041896 A1 20020411 US 2001-798824 20010302 <--
US 6610317 B2 20030826
NO 2001005753 A 20020128 NO 2001-5753 20011126 <--
ZA 2001010347 A 20030730 ZA 2001-10347 20011218 <--
PRAI US 1999-136323P P 19990527 <--
US 1999-158659P P 19991008 <--
US 1999-433486 A 19991104 <--
US 2000-186310P P 20000302 <--
WO 2000-US14578 W 20000525 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000072827	ICM	A61K009-16
US 6395300	ECLA	A61K009/16P4; A61K009/16P2 <--
US 2002041896	ECLA	A61K009/16H4B; A61K009/16H6B; A61K009/16H2; A61K009/16P4 <--

AB Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissoln. of the drug in aqueous media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solns., and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. Paclitaxel or docetaxel can be provided in a porous matrix form, which allows the drug to be formulated without solubilizing agents and administered as a bolus. For example, a nifedipine-loaded organic solution was prepared by dissolving 9.09 g of PEG 3350, 2.27 g of nifedipine, and 0.009 g of lecithin in 182 mL of methylene chloride. An aqueous solution was prepared by dissolving 3.27 g of NH4HCO3 and 0.91 g of PEG 3350 in 1.82 mL of water. The aqueous and organic solns. were homogenized and resulting emulsion

was spray dried. A suspension of the porous nifedipine drug matrix was prepared in 5% dextrose solution at a concentration of 2.5 mg/mL. A bolus injection of the suspension was tolerated when administrated to dogs.

ST drug solubilization polymer sugar porous matrix; microparticle oral parenteral drug porous matrix

IT Artery
Bone
Eye
Heart
Lung
Mucous membrane
Neoplasm
Skin
Synovial fluid
(administration to; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT Drug delivery systems
(bolus, injections, i.v.; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT Drug delivery systems
(buccal; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT Drug delivery systems
(capsules; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT Estrogens
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(conjugated; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT **Eye**
(conjunctiva, administration to; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT Drying
(fluidized-bed; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT Pore
(forming agents; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT Polymers, biological studies
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(hydrophilic; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT Drug delivery systems
(injections, i.m.; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT Drug delivery systems
(injections, i.v.; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT Drug delivery systems
(injections, s.c.; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT Drug delivery systems
(intracranial; preparation of porous matrixes containing hydrophilic polymers

and sugars for enhancement of drug dissoln.)
IT Drug delivery systems
(intratracheal; preparation of porous matrixes containing hydrophilic polymers
and sugars for enhancement of drug dissoln.)
IT Drug delivery systems
(microparticles; preparation of porous matrixes containing hydrophilic polymers
and sugars for enhancement of drug dissoln.)
IT Drug delivery systems
(mucosal; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)
IT Drug delivery systems
(nasal; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)
IT Drug delivery systems
(oral; preparation of porous matrixes containing hydrophilic polymers and sugars
for enhancement of drug dissoln.)
IT Drug delivery systems
(parenterals; preparation of porous matrixes containing hydrophilic polymers and
sugars for enhancement of drug dissoln.)
IT Drug delivery systems
(powders; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)
IT Dissolution rate
Emulsions
Evaporation
Freeze drying
Particle size
Solubilization
Surface area
Suspensions
Wetting agents
(preparation of porous matrixes containing hydrophilic polymers and sugars for
enhancement of drug dissoln.)
IT Interferons
Interleukins
Taxanes
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of porous matrixes containing hydrophilic polymers and sugars for
enhancement of drug dissoln.)
IT Carbohydrates, biological studies
Lecithins
Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of porous matrixes containing hydrophilic polymers and sugars for
enhancement of drug dissoln.)
IT Drug delivery systems
(rectal; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)
IT Volatile substances
(solvents; preparation of porous matrixes containing hydrophilic polymers and
sugars for enhancement of drug dissoln.)
IT Drying
(spray; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT Drug delivery systems
(sublingual; preparation of porous matrixes containing hydrophilic polymers and
sugars for enhancement of drug dissoln.)
IT Drug delivery systems
(suppositories, vaginal; preparation of porous matrixes containing hydrophilic
polymers and sugars for enhancement of drug dissoln.)
IT Drug delivery systems
(suppositories; preparation of porous matrixes containing hydrophilic polymers
and sugars for enhancement of drug dissoln.)
IT Drug delivery systems
(tablets; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)
IT Drug delivery systems
(topical; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)
IT Drying
(vacuum; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)
IT Drug delivery systems
(vaginal; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)
IT Salts, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(volatile, pore forming agents; preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)
IT Solvents
(volatile; preparation of porous matrixes containing hydrophilic polymers and
sugars for enhancement of drug dissoln.)
IT 631-61-8, Ammonium acetate 1066-33-7, Ammonium bicarbonate 1863-63-4, Ammonium benzoate 12125-02-9, Ammonium chloride, uses
RL: NUU (Other use, unclassified); USES (Uses)
(preparation of porous matrixes containing hydrophilic polymers and sugars for
enhancement of drug dissoln.)
IT 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide 50-99-7, Dextrose, biological studies 52-53-9, Verapamil 53-03-2, Prednisone 55-98-1, Busulfan 57-63-6, Ethinyl estradiol 58-61-7, Adenosine, biological studies 59-92-7, Levodopa, biological studies 67-78-7 67-97-0, Vitamin D3 67-97-0D, Vitamin D3, analogs 71-58-9, Medroxyprogesterone acetate 75-64-9, Erbumine, biological studies 77-36-1, Chlorthalidone 89-57-6, Mesalamine 126-07-8, Griseofulvin 128-13-2, Ursodiol 298-46-4, Carbamazepine 302-79-4, Tretinoin 321-64-2, Tacrine **363-24-6**, Dinoprostone 437-38-7, Fentanyl 439-14-5, Diazepam 443-48-1, Metronidazole 518-28-5, Podofilox **745-65-3**, Alprostadil 846-49-1, Lorazepam 1951-25-3, Amiodarone 3239-44-9, Dexfenfluramine 4759-48-2, Isotretinoin 5534-09-8, Beclomethasone dipropionate 5593-20-4, Betamethasone dipropionate 9002-68-0, Follitropin 9002-72-6, Growth hormone 9007-12-9, Calcitonin 9041-93-4, Bleomycin sulfate 10238-21-8, Glyburide 11096-26-7, Erythropoietin 12629-01-5, Somatropin 12633-72-6, Amphotericin 13311-84-7, Flutamide 15307-79-6, Diclofenac sodium 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 18559-94-9, Albuterol 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22204-53-1, Naproxen 27203-92-5, Tramadol 28860-95-9, Carbidopa 28981-97-7, Alprazolam 29094-61-9, Glipizide 30516-87-1, Zidovudine 32986-56-4, Tobramycin 33069-62-4, Paclitaxel 34911-55-2, Bupropion 36505-84-7, Buspirone 40391-99-9 41340-25-4, Etodolac 41575-94-4, Carboplatin 42399-41-7, Diltiazem 42924-53-8, Nabumetone 51022-70-9, Albuterol sulfate 51333-22-3, Budesonide 51773-92-3,

Mefloquine hydrochloride 54143-55-4, Flecainide 54527-84-3, Nicardipine hydrochloride 54910-89-3, Fluoxetine 54965-21-8, Albendazole 54965-24-1, Tamoxifen citrate 55268-75-2, Cefuroxime 56124-62-0, Valrubicin 56180-94-0, Acarbose 59729-33-8, Citalopram 60142-96-3, Gabapentin 60205-81-4, Ipratropium 63659-18-7, Betaxolol 65277-42-1, Ketoconazole 66085-59-4, Nimodipine 66376-36-1, Alendronate 66852-54-8, Halobetasol propionate 69655-05-6, Didanosine 70476-82-3, Mitoxantrone hydrochloride 72432-03-2, Miglitol 72509-76-3, Felodipine 72558-82-8, Ceftazidime 72956-09-3, Carvedilol 73384-59-5, Ceftriaxone 73590-58-6, Omeprazole 75330-75-5, Lovastatin 75695-93-1, Isradipine 75847-73-3, Enalapril 76095-16-4, Enalapril maleate 76547-98-3, Lisinopril 76824-35-6, Famotidine 76963-41-2, Nizatidine 77883-43-3, Doxazosin mesylate 78246-49-8, Paroxetine hydrochloride 78628-80-5, Terbinafine hydrochloride 78755-81-4, Flumazenil 79517-01-4, Octreotide acetate 79559-97-0, Sertraline hydrochloride 79794-75-5, Loratadine 79902-63-9, Simvastatin 80274-67-5, Metoprolol fumarate 81098-60-4, Cisapride 81103-11-9, Clarithromycin 82410-32-0, Ganciclovir 82752-99-6, Nefazodone hydrochloride 82834-16-0, Perindopril 83799-24-0, Fexofenadine 83905-01-5, Azithromycin 83919-23-7, Mometasone furoate 84625-61-6, Itraconazole 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86541-74-4, Benazepril hydrochloride 86541-75-5, Benazepril 87679-37-6, Trandolapril 89778-27-8, Toremifene citrate 91161-71-6, Terbinafine 91421-42-0, Rubitecan 93413-69-5, Venlafaxine 93957-54-1, Fluvastatin 95058-81-4, Gemcitabine 95233-18-4, Atovaquone 97048-13-0, Urofollitropin 97322-87-7, Troglitazone 98048-97-6, Fosinopril 98079-52-8, Lomefloxacin hydrochloride 98319-26-7, Finasteride 99011-02-6, Imiquimod 99294-93-6, Zolpidem tartrate 100286-90-6, Irinotecan hydrochloride 100986-85-4, Levofloxacin 103577-45-3, Lansoprazole 103628-48-4, Sumatriptan succinate 103775-10-6, Moexipril 104227-87-4, Famciclovir 104632-25-9, Pramipexole dihydrochloride 106266-06-2, Risperidone 106463-17-6, Tamsulosin hydrochloride 106685-40-9, Adapalene 107753-78-6, Zafirlukast 109889-09-0, Granisetron 110871-86-8, Sparfloxacin 111470-99-6, Amlodipine besylate 111974-72-2, Quetiapine fumarate 112809-51-5, Letrozole 113806-05-6, Olopatadine 114798-26-4, Losartan 114977-28-5, Docetaxel 115956-12-2, Dolasetron 120014-06-4, Donepezil 124832-26-4, Valacyclovir 127779-20-8, Saquinavir 131918-61-1, Paricalcitol 132539-06-1, Olanzapine 134308-13-7, Tolcapone 134678-17-4, Lamivudine 137862-53-4, Valsartan 140678-14-4, Mangafodipir trisodium 142373-60-2, Tirofiban hydrochloride 143011-72-7, Granulocyte colony-stimulating factor 144701-48-4, Telmisartan 145040-37-5, Candesartan cilexetil 147059-72-1, Trovafloxacin 147245-92-9, Glatiramer acetate 150378-17-9, Indinavir 154248-97-2, Imiglucerase 154598-52-4, Efavirenz 155141-29-0, Rosiglitazone maleate 155213-67-5, Ritonavir 158966-92-8, Montelukast 159989-65-8, Nelfinavir mesylate 161814-49-9, Amprenavir 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 171599-83-0, Sildenafil citrate 679809-58-6, Enoxaparin sodium
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT 64-17-5, Ethanol, biological studies 9003-43-4, Polyvinylpyrrolidine **9005-65-6**, Tween 80 25322-68-3, Polyethylene glycol 26266-57-9, Span 40 106392-12-5, Pluronic F127 211733-74-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of porous matrixes containing hydrophilic polymers and sugars for enhancement of drug dissoln.)

IT **363-24-6**, Dinoprostone **745-65-3**, Alprostadil
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic

use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of porous matrixes containing hydrophilic polymers and sugars for
enhancement of drug dissoln.)
RN 363-24-6 HCAPLUS
CN Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 745-65-3 HCAPLUS
CN Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **9005-65-6**, Tween 80
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of porous matrixes containing hydrophilic polymers and sugars for
enhancement of drug dissoln.)
RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L116 ANSWER 17 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN **1999:715858** HCAPLUS
DN **132:185338**
ED Entered STN: 10 Nov 1999
TI Stability and preparation of dispersion of misoprostol-HPMC
AU Chen, Liangkang; Chen, Hailin; Zhang, Guoqing; Chen, Jianxing
CS Shanghai Institute of Planned Parenthood Research, Shanghai, 200032, Peop. Rep. China
SO Shenyang Yaoke Daxue Xuebao (**1999**), 16(Suppl.), 4-6
CODEN: SYDXFF; ISSN: 1006-2858
PB Shenyang Yaoke Daxue Xuebao Bianjibu
DT Journal

LA Chinese
CC 63-6 (Pharmaceuticals)
AB The misoprostol-HPMC solid dispersions were prepared by a solvent evaporating method. The ratio of misoprostol to HPMC was 1:100, the **viscosity** of HPMC was E5. The stability of misoprostol was significantly improved by the method of solid dispersion HPMC.
ST misoprostol HPMC solid dispersion prepn stability
IT Drug delivery systems
(liqs., dispersions; stability and preparation of misoprostol-HPMC dispersion)
IT **9004-65-3**, HPMC **59122-46-2**, Misoprostol
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stability and preparation of misoprostol-HPMC dispersion)
IT **9004-65-3**, HPMC **59122-46-2**, Misoprostol
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stability and preparation of misoprostol-HPMC dispersion)
RN 9004-65-3 HCAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

H_3C-OH

CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 59122-46-2 HCAPLUS
CN Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11α,13E)-(±)- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



L116 ANSWER 18 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:659274 HCAPLUS
DN 131:291295
ED Entered STN: 15 Oct 1999
TI Gelling **ophthalmic** compositions containing xanthan gum
IN Bawa, Rajan; Hall, Rex E.; Kabra, Bhagwati P.; Teague, James E.
PA Alcon Laboratories, Inc., USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K047-36
CC 63-6 (Pharmaceuticals)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9951273	A1	19991014	WO 1999-US6106	19990326	<--
	W: AU, BR, CA, CN, JP, KR, MX, NZ, TR, ZA					
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	CA 2322579	AA	19991014	CA 1999-2322579	19990326	<--
	CA 2322579	C	20010828			
	AU 9931947	A1	19991025	AU 1999-31947	19990326	<--
	AU 740586	B2	20011108			
	BR 9910113	A	20001226	BR 1999-10113	19990326	<--
	EP 1069913	A1	20010124	EP 1999-913997	19990326	<--
	EP 1069913	B1	20030723			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
	TR 200002848	T2	20010221	TR 2000-200002848	19990326	<--
	NZ 506921	A	20020201	NZ 1999-506921	19990326	<--
	JP 2002510654	T2	20020409	JP 2000-542043	19990326	<--
	AT 245451	E	20030815	AT 1999-913997	19990326	<--
	PT 1069913	T	20031128	PT 1999-913997	19990326	<--
	CN 1133466	B	20040107	CN 1999-804558	19990326	<--
	ES 2203103	T3	20040401	ES 1999-913997	19990326	<--
	ZA 2000004413	A	20010522	ZA 2000-4413	20000825	<--
	HK 1031335	A1	20040121	HK 2001-102143	20010324	<--
PRAI	US 1998-81004P	P	19980407	<--		
	WO 1999-US6106	W	19990326	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9951273	ICM	A61K047-36

AB **Ophthalmic** drug delivery vehicles which are administrable as a liquid and which gel upon contact with the **eye** are disclosed. The vehicles contain xanthan gum (I). An **ophthalmic** composition contained timolol maleate 0.34, benzododecinium bromide 0.012, I 0.6, tromethamine 0.72, boric acid 0.3, mannitol 4.35, Polysorbate 80 0.05, and

water q.s. 100%.
ST **ophthalmic** gel xanthan gum timolol
IT pH
(adjusting agents; gelling **ophthalmic** compns. containing xanthan gum)
IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; gelling **ophthalmic** compns. containing xanthan gum)
IT Cosmetics
(emollients; gelling **ophthalmic** compns. containing xanthan gum)
IT Allergy inhibitors
Anti-infective agents
Antiglaucoma agents
Buffers
Immunosuppressants
Lubricants
Preservatives
Solubilizers
Stabilizing agents
Surfactants
(gelling **ophthalmic** compns. containing xanthan gum)
IT Growth factors, animal
Steroids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gelling **ophthalmic** compns. containing xanthan gum)
IT Drug delivery systems
(gels, **ophthalmic**; gelling **ophthalmic** compns. containing xanthan gum)
IT Anti-inflammatory agents
(nonsteroidal; gelling **ophthalmic** compns. containing xanthan gum)
IT Anti-inflammatory agents
(steroidal; gelling **ophthalmic** compns. containing xanthan gum)
IT 50-70-4, Sorbitol, biological studies 69-65-8, Mannitol 77-86-1
7281-04-1, Benzododecinium bromide **9005-65-6**, Polysorbate 80
10043-35-3, Boric acid, biological studies 11138-66-2, Xanthan gum
26839-75-8, Timolol 26921-17-5, Timolol maleate 32986-56-4, Tobramycin
49697-38-3, Rimexolone 51781-06-7, Carteolol 59803-98-4, Brimonidine
63659-19-8, Betaxolol hydrochloride 85721-33-1, Ciprofloxacin
113806-05-6, Olopatadine 116209-55-3, (S)-Betaxolol hydrochloride
130209-82-4, **Latanoprost** **135646-98-9**,
15-Ketolatanoprost 140462-76-6, Olopatadine hydrochloride
246145-93-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gelling **ophthalmic** compns. containing xanthan gum)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Carrington, S; POLYMER 1996, V37(13), P2871 HCAPLUS
(2) Colgate Palmolive Co; EP 0331617 A 1989 HCAPLUS
(3) Lin, S; US 4136177 A 1979 HCAPLUS
(4) Nolte, H; CARBOHYDRATE POLYMERS 1992, V18(4), P243 HCAPLUS
(5) Shatwell, K; CARBOHYDRATE RESEARCH 1990, V206(1), P87 HCAPLUS
IT **9005-65-6**, Polysorbate 80 **130209-82-4**,
Latanoprost **135646-98-9**, 15-Ketolatanoprost
246145-93-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gelling **ophthalmic** compns. containing xanthan gum)
RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 130209-82-4 HCAPLUS

CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 135646-98-9 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxo-5-phenylpentyl)cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 246145-93-7 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-, 1-methylethyl ester, (5Z)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



L116 ANSWER 19 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:705958 HCAPLUS

DN 129:321195
ED Entered STN: 06 Nov 1998
TI Thermally gelling emulsions comprising cellulose ethers
IN Kabra, Bhagwati P.
PA Alcon Laboratories, Inc., USA
SO U.S., 6 pp., Cont.-in-part of U.S. 5,618,800.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-715
ICS A01N043-04; C08B011-00; C08B011-08
NCL 514057000
CC 63-6 (Pharmaceuticals)
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5827835	A	19981027	US 1996-758787	19961203 <--
	US 5618800	A	19970408	US 1995-518289	19950823 <--
PRAI	US 1994-298244	B2	19940830 <--		
	US 1995-518289	A2	19950823 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5827835	ICM	A61K031-715
	ICS	A01N043-04; C08B011-00; C08B011-08
	NCL	514057000

AB Thermally gelling emulsion compns. which reversibly increase in either loss modulus or storage modulus, or both, upon contact with the **eye**, skin, mucous membrane or body cavity are disclosed. The emulsion compns. contain one or more nonionic substituted cellulose ethers and do not require a charged surfactant or a pH-sensitive polymer for such increase in loss modulus or storage modulus, or both, upon administration. In one embodiment, the compns. gel upon instillation in the **eye**. Thus, 0.3 g of methylethyl cellulose (I), 0.35 g of mannitol, 0.3 g of boric acid, and 0.066 g of tromethamine were combined with enough water to give 9.5 g of a composition I was hydrated by stirring the solution in an ice bath for 2 h. To this stirred composition, 0.5 g of Myritol 318 (caprylic/capric triglyceride) was added and the resulting mixture was stirred for fifteen minutes at room temperature to produce an emulsion.

ST thermal gelling pharmaceutical emulsion cellulose ether
IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(animal; thermally gelling emulsions comprising cellulose ethers)
IT Drug delivery systems
(emulsions; thermally gelling emulsions comprising cellulose ethers)
IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(esters; thermally gelling emulsions comprising cellulose ethers)
IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated; thermally gelling emulsions comprising cellulose ethers)
IT Antihypertensives
(post-surgical; thermally gelling emulsions comprising cellulose ethers)
IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sesame; thermally gelling emulsions comprising cellulose ethers)
IT Anti-inflammatory agents
(steroidal and non-steroidal; thermally gelling emulsions comprising cellulose ethers)
IT Allergy inhibitors
Anti-infective agents
Antiglaucoma agents

Dopamine agonists
Emulsifying agents
Immunosuppressants
Surfactants
(thermally gelling emulsions comprising cellulose ethers)
IT Corn oil
Growth factors, animal
Hydrocarbon oils
Phospholipids, biological studies
Prostaglandins
Proteins, general, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thermally gelling emulsions comprising cellulose ethers)
IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable; thermally gelling emulsions comprising cellulose ethers)
IT 124-07-2D, Caprylic acid, triglycerides 334-48-5D, Capric acid, triglycerides 9002-96-4 9003-11-6, Polyethylene oxide polypropylene oxide copolymer **9004-58-4**, Ethylhydroxyethylcellulose. **9004-59-5**, Methylethylcellulose **9005-65-6**, Polyoxyethylene sorbitan monooleate 25301-02-4, Oxyethylated tertiary octylphenol formaldehyde polymer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thermally gelling emulsions comprising cellulose ethers)
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Anon; EP 0227494 B1 1987 HCAPLUS
(2) Anon; WO 8911503 1989 HCAPLUS
(3) Anon; WO 9209307 1992 HCAPLUS
(4) Anon; JP WO9423750 1994
(5) Ansmann; US 4798682 1989 HCAPLUS
(6) Carlsson; US 5279660 1994 HCAPLUS
(7) Carlsson; Colloids and Surfaces 1990, V47, P147 HCAPLUS
(8) Chang; US 5296228 1994 HCAPLUS
(9) Clement; US 5208028 1993 HCAPLUS
(10) Davis; US 5192535 1993 HCAPLUS
(11) Greminger; Chapter XXVIII 1973, P619 HCAPLUS
(12) Haslam; US 4474751 1984 HCAPLUS
(13) Haslam; US 4474752 1984 HCAPLUS
(14) Henry; US 5126141 1992 HCAPLUS
(15) Hoeg; US 5441732 1995 HCAPLUS
(16) Joshi; US 5252318 1993 HCAPLUS
(17) Jullander; Acta Chemica Scandinavica 1955, V9, P1291 HCAPLUS
(18) Krezanoski; US 4188373 1980 HCAPLUS
(19) Lin; US 4136177 1979 HCAPLUS
(20) Lin; US 4136178 1979 HCAPLUS
(21) Marlin; US 5358706 1994 HCAPLUS
(22) Mazuel; US 4861760 1989 HCAPLUS
(23) Missel; US 5212162 1993 HCAPLUS
(24) Phares; US 3608073 1971 HCAPLUS
(25) Pramoda; US 4136173 1979 HCAPLUS
(26) Safwat; J of Controlled Release 1994, V32, P259 HCAPLUS
(27) Sarkar; US 4001211 1977 HCAPLUS
(28) Sarkar; J of Applied Polymer Science 1979, V24, P1073 HCAPLUS
(29) Shimokawa; US 4708821 1987 HCAPLUS
(30) Viegas; US 5077033 1991 HCAPLUS
(31) Viegas; US 5124151 1992 HCAPLUS
(32) Viegas; US 5143731 1992 HCAPLUS
(33) Viegas; US 5306501 1994 HCAPLUS
(34) Viegas; US 5318780 1994 HCAPLUS
IT **9004-58-4**, Ethylhydroxyethylcellulose. **9004-59-5**, Methylethylcellulose **9005-65-6**, Polyoxyethylene sorbitan monooleate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thermally gelling emulsions comprising cellulose ethers)
RN 9004-58-4 HCAPLUS
CN Cellulose, ethyl 2-hydroxyethyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 107-21-1
CMF C2 H6 O2



CM 3

CRN 64-17-5
CMF C2 H6 O



RN 9004-59-5 HCAPLUS
CN Cellulose, ethyl methyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

CM 3

CRN 64-17-5
CMF C2 H6 O



RN 9005-65-6 HCAPLUS

CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L116 ANSWER 20 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:635653 HCAPLUS
DN 129:265480
ED Entered STN: 08 Oct 1998
TI Compositions and methods for reducing **ocular** hypertension
IN Reed, Kenneth Warren; Yen, Shau-fong; Sou, Mary; Peacock, Regina Flinn
PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-557
ICS A61K009-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9841208	A1	19980924	WO 1998-EP1483	19980313 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2280089	AA	19980924	CA 1998-2280089	19980313 <--
AU 9870353	A1	19981012	AU 1998-70353	19980313 <--
AU 738781	B2	20010927		
EP 969846	A1	20000112	EP 1998-916948	19980313 <--
EP 969846	B1	20040107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI				
BR 9808016	A	20000308	BR 1998-8016	19980313 <--
EE 9900410	A	20000417	EE 1999-410	19980313 <--
EE 4091	B1	20030815		
NZ 337322	A	20010525	NZ 1998-337322	19980313 <--
JP 2001515502	T2	20010918	JP 1998-540126	19980313 <--
RU 2197970	C2	20030210	RU 1999-121641	19980313 <--
AT 257385	E	20040115	AT 1998-916948	19980313 <--
ZA 9802188	A	19980917	ZA 1998-2188	19980316 <--
TW 527187	B	20030411	TW 1998-87103809	19980316 <--
MX 9908471	A	20000228	MX 1999-8471	19990915 <--
NO 9904481	A	19990916	NO 1999-4481	19990916 <--
PRAI US 1997-819221	A	19970317 <--		
WO 1998-EP1483	W	19980313 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9841208	ICM	A61K031-557
	ICS	A61K009-00

AB Disclosed is an improved **ophthalmic** composition, including prostaglandin active agents, which is especially useful in lowering **intraocular** pressure (IOP) associated with glaucoma. Improvements in IOP reduction efficacy, preservative efficacy and reduced additive concns. are achieved by utilizing the disclosed compns. which include a prostaglandin

active agent (e.g., iso-Pr **unoprostone**, a metabolite of an F-series prostaglandin), in conjunction with selected non-ionic surfactants, preservatives, and non-ionic tonicity adjusting agents. An **eye** solution contained iso-Pr **unoprostone** 0.18, Polysorbate-80 0.7, Brij-97 0.3, benzalkonium chlorides 0.011, EDTA 0.02, mannitol 4.7, and distilled water to 100 %. Instillation of .apprx.30 μL of the solution into the **eye** of a rabbit resulted in the reduction of IOP to 86 % of the initial IOP.

ST glaucoma prostaglandin **ophthalmic** soln; **intraocular** pressure redn **isopropylunoprostone eye** drop

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; **ophthalmic** compns. containing prostaglandins with preservatives and tonicity-adjusting agents for reducing **ocular** hypertension)

IT Antiglaucoma agents
Glaucoma (disease)
Preservatives
Surfactants
(**ophthalmic** compns. containing prostaglandins with preservatives and tonicity-adjusting agents for reducing **ocular** hypertension)

IT Esters, biological studies
Phenols, biological studies
Polyoxyalkylenes, biological studies
Prostaglandins
Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**ophthalmic** compns. containing prostaglandins with preservatives and tonicity-adjusting agents for reducing **ocular** hypertension)

IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(salts, tall oil, sodium salts; **ophthalmic** compns. containing prostaglandins with preservatives and tonicity-adjusting agents for reducing **ocular** hypertension)

IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sodium salts; **ophthalmic** compns. containing prostaglandins with preservatives and tonicity-adjusting agents for reducing **ocular** hypertension)

IT Drug delivery systems
(solns., **ophthalmic**; **ophthalmic** compns. containing prostaglandins with preservatives and tonicity-adjusting agents for reducing **ocular** hypertension)

IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tall-oil, sodium salts; **ophthalmic** compns. containing prostaglandins with preservatives and tonicity-adjusting agents for reducing **ocular** hypertension)

IT 50-70-4, D-Sorbitol, biological studies 54-64-8, Thimerosal 55-56-1, Chlorhexidine **56-81-5**, Glycerol, biological studies 57-09-0, Cetyltrimethylammonium bromide 57-15-8, Chlorbutanol 59-50-7, 3-Methyl-4-chlorophenol 60-00-4, EDTA, biological studies 60-12-8, Phenylethyl alcohol 69-65-8, D-Mannitol 80-46-6, 4-tert-Amylphenol 88-04-0, Chloroxylenol 90-43-7, 2-Phenylphenol 97-23-4, Dichlorphen 98-54-4, 4-tert-Butylphenol 99-96-7D, p-Hydroxybenzoic acid, esters 100-51-6, Benzylalcohol, biological studies 106-41-2, p-Bromophenol 106-48-9, p-Chlorophenol 117-80-6, 2,3-Dichloro-1,4-naphthoquinone 120-32-1, 2-Benzyl-4-chlorophenol 121-54-0, Benzethonium chloride 122-99-6, Phenoxyethanol 123-03-5, Cetylpyridinium chloride 148-24-3, 8-Hydroxyquinoline, biological studies 1331-61-9, Dodecylbenzene sulfonic acid ammonium salt 1405-20-5, Polymyxin B sulfate 3772-94-9,

Pentachlorophenyllaurate 3944-72-7, 1-Octane sulfonic acid 5964-24-9, Thimerfonate sodium 9004-98-2, Brij 97 **9005-65-6**, Polysorbate 80 13081-16-8, 4-Chloro-2-pentylphenol 13347-42-7, 2-Cyclopentyl-4-chlorophenol 19379-90-9, Benzoxonium chloride 25155-19-5, Naphthalene sulfonic acid 25155-30-0, Dodecylbenzene sulfonic acid sodium salt 25322-68-3, Polyethylene glycol 25322-69-4, Polypropylene glycol 27177-77-1, Dodecylbenzene sulfonic acid potassium salt 28757-47-3 67993-50-4 85721-33-1, Ciprofloxacin 88951-32-0 **120373-24-2**, **Isopropyl unoprostone**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**ophthalmic** compns. containing prostaglandins with preservatives and tonicity-adjusting agents for reducing **ocular** hypertension)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Alcon Laboratories; WO 9530420 A 1995 HCAPLUS
(2) Allergan Inc; WO 9213836 A 1992 HCAPLUS
(3) Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo; EP 0458587 A 1991 HCAPLUS
(4) Suketu, D; US 5558876 A 1996 HCAPLUS

IT **56-81-5**, Glycerol, biological studies **9005-65-6**, Polysorbate 80 **120373-24-2**, **Isopropyl unoprostone**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**ophthalmic** compns. containing prostaglandins with preservatives and tonicity-adjusting agents for reducing **ocular** hypertension)

RN 56-81-5 HCAPLUS
CN 1,2,3-Propanetriol (9CI) (CA INDEX NAME)



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 120373-24-2 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L116 ANSWER 21 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:527193 HCAPLUS

DN 129:166193
ED Entered STN: 21 Aug 1998
TI Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix
IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil
PA United States Dept. of the Army, USA; Van Hamont, John E.; et al.
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-52
ICS A61K047-30
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1, 2, 15
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832427	A1	19980730	WO 1998-US1556	19980127 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6309669	B1	20011030	US 1997-789734	19970127 <--
	AU 9863175	A1	19980818	AU 1998-63175	19980127 <--
PRAI	US 1997-789734	A	19970127 <--		
	US 1984-590308	B1	19840316 <--		
	US 1992-867301	A2	19920410 <--		
	US 1995-446148	A2	19950522 <--		
	US 1995-446149	B2	19950522 <--		
	US 1996-590973	B2	19960124 <--		
	WO 1998-US1556	W	19980127 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9832427	ICM	A61K009-52
	ICS	A61K047-30

AB Novel burst-free, sustained release biocompatible and biodegradable microcapsules are disclosed which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiol. environment. The microcapsules are comprised of a core of polypeptide or other biol. active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.
ST infection microcapsule sustained release peptide copolymer
IT Hepatitis
(B, chronic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Hepatitis
(C, chronic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Trypanosoma cruzi
(Chagas' disease from; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Immunoglobulins
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological

study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(G, ampicillin-specific; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Nervous system
(Huntington's chorea; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antitumor agents
(Kaposi's sarcoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Sperm
(acrosome, proteinase of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Diagnosis
(agents; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Ragweed (Ambrosia)
(allergy; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Ameba
(amebiasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antibiotics
(aminoglycoside; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Absidia ramosa
Actinobacillus equuli
Actinobacillus seminis
Arcanobacterium pyogenes
Aspergillus fumigatus
Babesia caballi
Brucella melitensis
Campylobacter fetus
Campylobacter fetus intestinalis
Candida albicans
Candida tropicalis
Chlamydia psittaci
Clostridium tetani
Equid herpesvirus 1
Equine arteritis virus
Escherichia coli
Gardnerella vaginalis
Human herpesvirus 1
Human herpesvirus 2
Leptospira interrogans pomona
Listeria monocytogenes
Mycobacterium tuberculosis
Mycoplasma bovigenitalium
Mycoplasma hominis
Neisseria gonorrhoeae
Pneumocystis carinii
Pseudomonas aeruginosa
Rhodococcus equi
Salmonella abortivoequina
Salmonella abortusovis
Streptococcus group B
Toxoplasma gondii
Treponema pallidum
Trichomonas vaginalis
Tritrichomonas foetus
Trypanosoma equiperdum

(antigens of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Mycobacterium
(antimycobacterial agents; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Mouth
(aphthous ulcer; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Drugs
(appetite stimulants; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Heart, disease
(arrhythmia; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Blood vessel
(artificial, infections surrounding; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Dermatitis
(atopic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Babesia
(babesiasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Skin, neoplasm
(basal cell carcinoma, inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Antitumor agents
Skin, neoplasm
(basal cell carcinoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Natural products, pharmaceutical
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(belladonna; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Prostate gland
(benign hyperplasia; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Polymers, biological studies
RL: DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biodegradable; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Nervous system
(central, disease; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Polymers, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(co-; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Intestine, disease
(colitis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Antigens
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(colony factor; prevention of infections with bioactive material

encapsulated within biodegradable-biocompatible polymeric matrix)
IT Intestine, neoplasm
(colorectal, inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Antitumor agents
Intestine, neoplasm
(colorectal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Thrombosis
(coronary arterial; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Artery, disease
(coronary, thrombosis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Vasodilators
(coronary; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Tapeworm (Cestoda)
(cysticercosis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Bladder
(cystitis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Mental disorder
(depression; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT **Eye, disease**
(**diabetic retinopathy**; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Polyesters, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(dilactone-based; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Digestive tract
(drugs for; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Brain, disease
(edema, peritumoral; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Drug delivery systems
(emulsions; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT B cell (lymphocyte)
T cell (lymphocyte)
(epitopes of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Alkaloids, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(ergot; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Amino acids, biological studies
Fats and Glyceridic oils, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(essential; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Fasciola
(fascioliasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Filaria
(filariasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Anthelmintics
(filaricides; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Digestive tract
(gastroenteritis, virus causing; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Intestine, disease
(giardiasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Transplant and Transplantation
(graft-vs.-host reaction; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Calymmatobacterium granulomatis
(granuloma inguinale from, antigens of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Antigens
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hepatitis B surface; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Liver, neoplasm
(hepatoma, inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Antitumor agents
Liver, neoplasm
(hepatoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Human herpesvirus 2
(herpes genitalis from; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Human herpesvirus 3
(herpes zoster from, antigens of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Parvovirus
Retroviridae
(human; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Globulins, biological studies
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hyperimmune; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Sexual behavior
(impotence; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT **Eye, disease**
Mouth
Skin, disease
(**infection**; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Prosthetic materials and Prosthetics
(infections surrounding; prevention of infections with bioactive

material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Drug delivery systems
(inhalants; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Fertility
Ovary, neoplasm
Pancreas, neoplasm
(inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Drug delivery systems
(injections; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Diabetes mellitus
(insulin-dependent; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Leishmania
(leishmaniasis from, visceral; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Antitumor agents
(lung small-cell carcinoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Antibiotics
(macrolide; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Antitumor agents
(mammary gland; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Antitumor agents
(melanoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Drug delivery systems
(microcapsules; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Drug delivery systems
(microspheres; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Drug delivery systems
(nasal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Mammary gland
Prostate gland
(neoplasm, inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Mammary gland
Prostate gland
(neoplasm; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Meningitis
(neoplastic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Angiogenesis
(neovascularization, retinal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Diabetes mellitus
(non-insulin-dependent; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Anti-inflammatory agents
(nonsteroidal; prevention of infections with bioactive material

encapsulated within biodegradable-biocompatible polymeric matrix)
IT Emulsions
(oil-in-water; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Drug delivery systems
(oral; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Nitrites
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(organic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Antitumor agents
(ovary; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Antitumor agents
(pancreas; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Anxiety
(panic disorder; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Paragonimus
(paragonimiasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Hormones, animal, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptide; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Periodontium
(periodontitis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Mental disorder
(phobia; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Adhesion, biological
(postsurgical; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT AIDS (disease)
Acinetobacter
Actinomycetales
Adenoviridae
Adrenoceptor agonists
Aerococcus
Aeromonas
Allergy inhibitors
Alzheimer's disease
Analgesics
Anesthetics
Angiogenesis
Angiogenesis inhibitors
Anthelmintics
Anti-infective agents
Anti-inflammatory agents
Antiarrhythmics
Antiarthritics
Antibacterial agents
Antibiotics
Anticholesteremic agents
Anticoagulants
Anticonvulsants

Antidepressants
Antidiabetic agents
Antidiarrheals
Antiemetics
Antihistamines
Antihypertensives
Antimalarials
Antimigraine agents
Antiparkinsonian agents
Antipyretics
Antirheumatic agents
Antiserums
Antitumor agents
Antitussives
Antiulcer agents
Antiviral agents
Appetite depressants
Arbovirus
Arcanobacterium haemolyticum
Arenavirus
Asthma
Bacillus (bacterium genus)
Biocompatibility
Blood substitutes
Bordetella
Borrelia
Bronchodilators
Brucella
Cachexia
Calymmatobacterium
Campylobacter
Cardiopulmonary bypass
Cardiotonics
Cardiovascular agents
Cholinergic agonists
Clostridium
Contraceptives
Coronavirus
Corynebacterium
Cryptosporidium parvum
Cystic fibrosis
Cytomegalovirus
Cytotoxic agents
Decongestants
Diagnosis
Diarrhea
Dissolution rate
Diuretics
Drug bioavailability
Drug dependence
Ebola virus
Echinococcus
Electrolytes, biological
Emulsifying agents
Enterobacteriaceae
Enterococcus
Enterovirus
Epitopes
Erysipelothrix
Expectorants
Filovirus
Flavobacterium
Freeze drying

Fungicides
Gardnerella
Gram-negative bacteria
Gram-positive bacteria (Firmicutes)
Haemophilus
Haemophilus ducreyi
Helicobacter
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human immunodeficiency virus 1
Human parainfluenza virus
Human poliovirus
Hypercholesterolemia
Hypnotics and Sedatives
Immunization
Immunomodulators
Immunostimulants
Infection
Influenza virus
Kidney, disease
Lactococcus
Legionella
Leptospira
Leuconostoc
Listeria
Measles virus
Melanoma
Micrococcus
Molluscum contagiosum virus
Moraxella
Multiple sclerosis
Mumps virus
Muscle relaxants
Narcotics
Neisseria
Nervous system agents
Nutrients
Opioid antagonists
Osteoarthritis
Osteomyelitis
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Papillomavirus
Parasiticides
Parkinson's disease
Pediococcus
Planococcus (bacterium)
Plesiomonas
Pneumonia
Poxviridae
Pseudomonas
Psoriasis
Psychotropics
Rabies virus
Reoviridae
Respiratory syncytial virus
Rheumatoid arthritis
Rhinovirus

Rhodococcus
Rotavirus
Rothia (bacterium)
Rubella virus
Salmonella typhi
Sexually transmitted diseases
Shigella boydii
Shigella dysenteriae
Shigella flexneri
Shigella sonnei
Spirillum
Staphylococcus
Streptobacillus
Streptococcus
Thrombosis
Tranquilizers
Treponema
Vaccines
Vasodilators
Vibrio
Vibrio cholerae
Wolinella succinogenes
Yersinia
(prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Alkaloids, biological studies
Antibodies
Antigens
Enzymes, biological studies
Estrogens
Glycolipids
Glycopeptides
Growth factors, animal
Lipopolysaccharides
Peptides, biological studies
Pheromones, animal
Progestogens
Prostaglandins
Proteins, general, biological studies
Steroids, biological studies
Sulfonamides
Tetracyclines
Vitamins
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Drug delivery systems
(prodrugs; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Proliferation inhibition
(proliferation inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antitumor agents
(prostate gland; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Pilus
(proteins; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Scalp
(psoriasis of; prevention of infections with bioactive material

encapsulated within biodegradable-biocompatible polymeric matrix)
IT Drug delivery systems
(rectal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Artery, disease
(restenosis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT **Eye, disease**
(**retina, neovascularization**; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Schistosoma
(schistosomiasis from; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Lung, neoplasm
(small-cell carcinoma, inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Lung, neoplasm
(small-cell carcinoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Muscle relaxants
(spasmolytics; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Contraceptives
(spermicidal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Brain, disease
(spongiform encephalopathy, agent causing; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Appetite
(stimulants; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Brain, disease
(stroke; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Strongylus
(strongylodiasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Drug delivery systems
(sustained-release, programmable; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Osteoporosis
(therapeutic agents; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Bile
(therapy with; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Drug delivery systems
(topical; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Muscle, disease
(torticollis, spasmodic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Toxocara
(toxocariasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Toxoplasma gondii
(toxoplasmosis from; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Drug delivery systems
(transdermal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Head
(trauma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Trichinella
(trichinellosis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Trichomonas
(trichomoniasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Drug delivery systems
(vaginal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT Emulsions
(water-in-oil; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT **Lactams**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β -, **antibiotics**; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT 9002-72-6, Somatotropin
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(deficiency; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT 9005-49-6, Heparin, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(neutralization of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT 9001-60-9, Lactate dehydrogenase 37326-33-3, Hyaluronidase
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(of sperm; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
IT 50-06-6, Phenobarbital, biological studies 50-12-4, Mephenytoin 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-28-2, 17β-Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-52-2, Thioridazine 50-55-5, Reserpine 50-78-2, Aspirin 51-55-8, Atropine, biological studies 52-24-4, Thiotepa 52-76-6, Lynestrenol 53-03-2, Prednisone 53-16-7, Estrone, biological studies 53-86-1, Indomethacin 54-11-5, Nicotine 55-48-1, Atropine sulfate 55-63-0, Nitroglycerin 55-86-7, Nitrogen mustard 56-53-1, Diethyl stilbestrol 56-75-7, Chloramphenicol 57-27-2, Morphine, biological studies 57-33-0, Sodium pentobarbital 57-42-1, Meperidine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-85-2, Testosterone propionate 57-92-1, Streptomycin a, biological studies 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-22-0 58-25-3, Chlordiazepoxide 58-39-9, Perphenazine 58-73-1, Diphenhydramine 59-01-8, Kanamycin a 59-05-2, Methotrexate 59-92-7, L-Dopa, biological studies 61-33-6, Penicillin g, biological studies 67-20-9, Nitrofurantoin 68-22-4, Norethisterone 68-23-5, Norethynodrel 69-09-0, Chlorpromazine hydrochloride 69-53-4, Ampicillin 69-72-7D, Salicylic acid, derivs. 71-58-9, Medroxyprogesterone acetate 72-33-3, Mestranol 76-57-3, Codeine 79-57-2, Oxytetracycline 79-64-1, Dimethisterone 91-81-6, Tripelennamine 103-90-2, Acetaminophen 113-15-5, Ergotamine 114-07-8, Erythromycin 114-49-8, Hyoscine hydrobromide 121-54-0 122-09-8, Phentermine 125-29-1, Dihydrocodeinone 125-71-3, Dextromethorphan 127-48-0, Trimethadione 128-62-1, Noscapine 145-94-8, Chlorindanol 148-82-3, Melphalan

155-41-9, Methscopolamine bromide 288-32-4D, Imidazole, derivs.
297-76-7, Ethynodiol diacetate 302-22-7, Chlormadinone acetate
305-03-3, Chlorambucil 309-43-3, Sodium secobarbital 315-30-0,
Allopurinol 434-03-7, Ethisterone 439-14-5, Diazepam 443-48-1,
Metronidazole 469-62-5 471-34-1, Calcium carbonate, biological studies
497-19-8, Sodium carbonate, biological studies 523-87-5, Dimenhydrinate
546-93-0, Magnesium carbonate 578-66-5D, 8-Aminoquinoline, derivs.
578-68-7D, 4-Aminoquinoline, derivs. 595-33-5, Megestrol acetate
738-70-5, Trimethoprim 846-50-4, Temazepam 1397-89-3, Amphotericin b
1397-94-0, Antimycin a 1403-66-3, Gentamicin 1404-26-8, Polymyxin b
1404-90-6, Vancomycin 1406-05-9D, Penicillin, derivs. 4696-76-8,
Kanamycin b 5588-33-0, Mesoridazine 5633-18-1, Melengestrol
5786-21-0, Clozapine 5800-19-1, Metiapine 6533-00-2, Norgestrel
7447-40-7, Potassium chloride (KCl), biological studies 8063-07-8,
Kanamycin 9000-83-3, Atpase 9000-92-4, Amylase 9001-62-1, Lipase
9001-63-2, Muramidase 9001-67-6, Neuraminidase 9001-78-9, Alkaline
phosphatase 9001-99-4, Ribonuclease 9002-02-2, Succinic acid
dehydrogenase 9002-07-7, Trypsin 9004-07-3, Chymotrypsin 9004-10-8,
Insulin, biological studies 9025-82-5, Phosphodiesterase 9029-12-3,
Glutamic acid dehydrogenase 9035-74-9, Glycogen phosphorylase
9046-27-9, γ-Glutamyltranspeptidase 9079-67-8 10118-90-8,
Minocycline 11111-12-9, Cephalosporins 13292-46-1, Rifampin
14271-04-6 21645-51-2, Aluminum hydroxide, biological studies
22232-71-9, Mazindol 24730-10-7, Dihydroergocristine methanesulfonate
25447-66-9 26780-50-7, Poly(lactide co-glycolide) 26787-78-0,
Amoxicillin 30516-87-1, Azt 32986-56-4, Tobramycin 35189-28-7,
Norgestimate 37205-61-1, Proteinase inhibitor 37517-28-5, Amikacin
53678-77-6D, Muramyl dipeptide, derivs. 53994-73-3, Cefaclor
55268-75-2, Cefuroxime 61036-62-2, Teicoplanin 64221-86-9, Imipenem
80738-43-8, Lincosamide 81103-11-9, Clarithromycin 82419-36-1,
Ofloxacin 85721-33-1, Ciprofloxacin
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV
(Device component use); PRP (Properties); THU (Therapeutic use); BIOL
(Biological study); PROC (Process); USES (Uses)
(prevention of infections with bioactive material encapsulated within
biodegradable-biocompatible polymeric matrix)

IT 9002-60-2, Adrenocorticotropin, biological studies 9007-12-9, Calcitonin
9034-40-6, Lhrh 62229-50-9, Epidermal growth factor 115966-68-2,
Histatin 5 (human parotid saliva) 123781-17-9, Histatin 127716-52-3,
Histatin 9 (human parotid saliva) 146553-69-7 174270-18-9,
5-25-Histatin 6 (human parotid saliva) 186138-55-6 186138-60-3
194017-97-5 211118-03-5
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
(Properties); THU (Therapeutic use); BIOL (Biological study); PROC
(Process); USES (Uses)
(prevention of infections with bioactive material encapsulated within
biodegradable-biocompatible polymeric matrix)

IT **9005-64-5**, Tween 20 **9005-65-6**, Tween 80
9005-67-8, Tween 60 106392-12-5, Pluronic
RL: MOA (Modifier or additive use); PRP (Properties); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)
(prevention of infections with bioactive material encapsulated within
biodegradable-biocompatible polymeric matrix)

IT 75-09-2, uses
RL: NUU (Other use, unclassified); USES (Uses)
(prevention of infections with bioactive material encapsulated within
biodegradable-biocompatible polymeric matrix)

IT 146553-70-0 146553-71-1 146553-72-2 146553-73-3 146553-74-4
146553-75-5 146553-76-6 146553-77-7 146553-78-8 146553-81-3
146553-82-4 146553-83-5 146553-85-7 146553-86-8 146553-87-9
146553-88-0 146553-89-1 146553-90-4 146553-91-5 146553-92-6
164583-46-4 164583-50-0 164583-51-1 211118-14-8 211118-17-1
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Jeyanthi; Proceedings International Symposium on Controlled Release of Bioactive Materials 1996, P351 HCAPLUS
(2) Oppenheim; US 5486503 A 1996 HCAPLUS
(3) Syntex U S AInc; EP 0052510 B2 1994 HCAPLUS
(4) Wang; J of Controlled Release 1991, V17, P23 HCAPLUS
(5) Yan; J of Controlled Release 1994, V32(3), P231 HCAPLUS
(6) Yeh; A Novel Emulsification-Solvent Extraction Technique for Production of Protein Loaded Biodegradable Microparticles for Vaccine and Drug Delivery 1995, V33(3), P437 HCAPLUS
IT **9005-64-5**, Tween 20 **9005-65-6**, Tween 80
9005-67-8, Tween 60
RL: MOA (Modifier or additive use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
RN 9005-64-5 HCAPLUS
CN Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9005-67-8 HCAPLUS
CN Sorbitan, monooctadecanoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L116 ANSWER 22 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:197383 HCAPLUS
DN 128:275079
ED Entered STN: 06 Apr 1998
TI Pharmaceutical composition forming a gel
IN Carlfors, Johan; Lindell, Katarina
PA Carlfors, Johan, Swed.; Lindell, Katarina
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-00
ICS A61K047-48; A61K047-36; A61K047-38
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9811874	A1	19980326	WO 1997-SE1592	19970922 <--
	W: AU, CA, CN, JP, KR, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	SE 9603480	A	19980324	SE 1996-3480	19960923 <--
	AU 9744077	A1	19980414	AU 1997-44077	19970922 <--
	JP 2001501194	T2	20010130	JP 1998-514594	19970922 <--
PRAI	SE 1996-3480	A	19960923 <--		
	WO 1997-SE1592	W	19970922 <--		

CLASS
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 9811874	ICM	A61K009-00
	ICS	A61K047-48; A61K047-36; A61K047-38

AB An in situ gel forming pharmaceutical composition for local administration to a target organ in the body, said composition essentially consisting of a water solution containing one or more aggregate forming surfactants, one or more gel forming water soluble polymers, a drug and optionally excipients, said drug having lipophilic properties, as it binds stronger to the aggregates of surfactants than to water, whereby its release from the in situ forming gel to the target organ occurs slowly. A composition was prepared containing **latanoprost** 200 μg, Et hydroxyethyl cellulose 40 mg, cetyltrimethylammonium bromide 13 mg and water to 4g.

ST pharmaceutical gel; ethyl hydroxyethyl cellulose pharmaceutical gel

IT Quaternary ammonium compounds, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; pharmaceutical composition forming a gel)

IT Drug delivery systems
(gels; pharmaceutical composition forming a gel)

IT **Eye**
Lipophilicity
Nose
Preservatives
Surfactants
(pharmaceutical composition forming a gel)

IT Betaines
Glycerides, biological studies
Phospholipids, biological studies
Polysaccharides, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition forming a gel)

IT Osmotic pressure
(regulators; pharmaceutical composition forming a gel)

IT 151-21-3, Sodium dodecyl sulfate, biological studies 8044-71-1, Cetrimide 9000-07-1, Carrageenan **9004-58-4**, Ethyl hydroxyethyl cellulose 9004-61-9, Hyaluronic acid 9005-32-7, Alginic acid **9005-63-4D**, Polyoxyethylene sorbitan, esters 12441-09-7D, Sorbitan, esters 54514-50-0 71010-52-1D, Gellan gum, deacetylated 75345-27-6, Polyquad
RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical composition forming a gel)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 69267-58-9, Timolol hydrochloride **130209-82-4**, **Latanoprost**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical composition forming a gel)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Cabane, B; Macromolecules 1996, V29, P3188 HCAPLUS
(2) Goddard, E; J Soc Cosmet Chem 1990, V41, P23 HCAPLUS
(3) Katarina, E; International Journal of Pharmaceutics 1996, V137, P233

IT **9004-58-4**, Ethyl hydroxyethyl cellulose **9005-63-4D**, Polyoxyethylene sorbitan, esters
RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical composition forming a gel)

RN 9004-58-4 HCAPLUS

CN Cellulose, ethyl 2-hydroxyethyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 107-21-1
CMF C2 H6 O2



CM 3

CRN 64-17-5
CMF C2 H6 O



RN 9005-63-4 HCAPLUS
CN Sorbitan, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **130209-82-4, Latanoprost**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(pharmaceutical composition forming a gel)
RN 130209-82-4 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, 1-methylethyl ester, (5Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L116 ANSWER 23 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:124046 HCAPLUS
DN 128:196684
ED Entered STN: 28 Feb 1998
TI Pharmaceutical compositions containing a reverse thermally **viscosifying** polymer network
IN Ron, Eyal S.; Bromberg, Lev; Orkisz, Michal; Kearney, Marie; Luczak,

Scott; Timm, Mary J.; Wrobel, Stanley J.
PA Gel Sciences, Inc., USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K047-32
ICS A61K047-34
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9806438	A2	19980219	WO 1997-US13988	19970812 <--
	WO 9806438	A3	19980625		
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2263411	AA	19980219	CA 1997-2263411	19970812 <--
	EP 920338	A2	19990609	EP 1997-937165	19970812 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000516614	T2	20001212	JP 1998-509898	19970812 <--
PRAI	US 1996-23996P	P	19960812 <--		
	US 1996-25974P	P	19960916 <--		
	US 1996-28183P	P	19961015 <--		
	US 1996-30798P	P	19961114 <--		
	US 1997-34174P	P	19970102 <--		
	US 1997-34454P	P	19970102 <--		
	WO 1997-US13988	W	19970812 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9806438	ICM	A61K047-32
	ICS	A61K047-34

AB A pharmaceutic composition includes a pharmaceutically acceptable carrier, comprising a reverse thermally **viscosifying** polymer network. The polymer network includes at least one responsive polymer component, said responsive component capable of aggregation in solution in response to an environmental stimulus and at least one structural component, said structural component exhibiting self-repulsive interactions over use conditions. The responsive component is randomly bonded to said structural component and the polymer network characterized in that it **viscosifies** in response to said environmental stimulus. The composition further includes a pharmaceutically active agent which imparts a pharmaceutic effect, said carrier and said agent disposed within an aqueous-based medium. The composition is suitable for administration of the pharmaceutical agent across dermal, otic, rectal, vaginal, **ophthalmic**, esophageal and nasal mucosal membranes. A composition was prepared from Pluronic F27 and poly(acrylic acid).

ST pharmaceutical polyoxyalkylene acrylate **viscosifying**

IT Alcohols, biological studies
RL: POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C16-18; pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT Polyoxyalkylenes, biological studies
RL: POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acrylic; pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT Polysiloxanes, biological studies
RL: MOA (Modifier or additive use); POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(di-Me, 3-hydroxypropyl Me, ethers with polyethylene-polypropylene

glycol acetate; pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT Nervous system agents
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(miotics; pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT Drug delivery systems
(pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT Polysiloxanes, biological studies
RL: MOA (Modifier or additive use); POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT Adrenoceptor agonists
Analgesics
Anesthetics
Antacids
Anti-infective agents
Antiemetics
Antihistamines
Antihypertensives
Antipyretics
Antitumor agents
Antiulcer agents
Antiviral agents
Contraceptives
Decongestants
Diuretics
Flavor
Fungicides
Hormones, animal, biological studies
Laxatives
Minerals, biological studies
Muscarinic antagonists
Parkinson's disease
Prostaglandins
Steroids, biological studies
Tranquilizers
Vaccines
Viscosity
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing **a** reverse thermally **viscosifying** polymer network)

IT **Acrylic polymers, biological studies**
RL: POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyoxyalkylene-; pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT Muscle relaxants
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spasmolytics; pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT Contraceptives
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spermicidal; pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT Drug delivery systems
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sprays; pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT Adrenoceptor antagonists

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β-; pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT **56-81-5**, 1,2,3-Propanetriol, biological studies 67-63-0, Isopropanol, biological studies 77-92-9, Citric acid, biological studies 81-13-0, Panthenol 139-33-3, Disodium EDTA 872-50-4, biological studies 7447-40-7, Potassium chloride, biological studies 9016-45-9 9051-57-4, Rhodapex CO-436 12616-49-8, Plurafac C-17 26027-38-3, Nonoxynol 9 51410-72-1 74775-06-7, Crodamol PMP 81646-13-1 84517-95-3, Germaben II
RL: MOA (Modifier or additive use); POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT 60621-84-3P
RL: POF (Polymer in formulation); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT **9005-65-6**, Tween 80 106392-12-5, Pluronic L122
RL: POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT 54182-58-0, Sucralfate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

IT **56-81-5**, 1,2,3-Propanetriol, biological studies
RL: MOA (Modifier or additive use); POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

RN 56-81-5 HCAPLUS
CN 1,2,3-Propanetriol (9CI) (CA INDEX NAME)



IT **9005-65-6**, Tween 80
RL: POF (Polymer in formulation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing a reverse thermally **viscosifying** polymer network)

RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L116 ANSWER 24 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:262698 HCAPLUS
DN 126:321069
ED Entered STN: 24 Apr 1997
TI Thermally-gelling drug delivery vehicles containing cellulose ethers

IN Kabra, Bhagwati P.; Lang, John C.
PA Alcon Laboratories, Inc., USA
SO U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 298,244, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-715
ICS C08B011-02; C08B011-08
NCL 514057000
CC 63-5 (Pharmaceuticals)
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5618800	A	19970408	US 1995-518289	19950823 <--
	CA 2172373	AA	19960307	CA 1995-2172373	19950823 <--
	CA 2172373	C	19990316		
	CN 1134662	A	19961030	CN 1995-190826	19950823 <--
	ES 2162638	T3	20020101	ES 1995-931603	19950823 <--
	PT 725628	T	20020328	PT 1995-931603	19950823 <--
	TW 460288	B	20011021	TW 1995-84108938	19950828 <--
	US 5827835	A	19981027	US 1996-758787	19961203 <--
PRAI	US 1994-298244	B2	19940830 <--		
	US 1995-518289	A2	19950823 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5618800	ICM	A61K031-715
	ICS	C08B011-02; C08B011-08
	NCL	514057000

AB Drug delivery vehicles which reversibly increase in either loss modulus or storage modulus, or both, upon contact with the **eye**, skin, mucous membrane or body cavity are disclosed. The vehicles contain one or more nonionic substituted cellulose ethers and do not require a charged surfactant or a pH-sensitive polymer for such increase in loss modulus or storage modulus, or both, upon administration. In one embodiment, the vehicles gel upon instillation in the **eye.** A solution containing methylcellulose 2.5, disodium hydrogen phosphate and anhydrous sodium phosphate monohydrate 1.3% was prepared having osmolality of 291 mOsm and pH = 7.3. The **viscoelastic** properties of the solution in pre-dose (25°) and post-dose (35°) states were measured. At the end of the isotherm at 25°, G', G'', and G* values were about 4 Pa, 4 Pa, and 6 Pa resp. At the end of the isotherm at 35°, G', G'', G* values were about 7 Pa, 4 Pa, 8 Pa resp. Thus increasing temperature from 25°-35°, this solution did not gel and did not show a significant increase in storage modulus even though it contained an amount of phosphate salts sufficient to raise the osmolality of the solution to 293 mOsm.

ST drug delivery vehicle gelling cellulose ether
IT **Glaucoma (disease)**
(inhibitors; thermally-gelling drug delivery vehicles containing cellulose ethers)
IT Allergy inhibitors
Anti-inflammatory agents
Antibacterial agents
Antihypertensives
Dopamine agonists
Drug delivery systems
Immunosuppressants
(thermally-gelling drug delivery vehicles containing cellulose ethers)
IT Growth factors, animal
Prostaglandins
Proteins, general, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(thermally-gelling drug delivery vehicles containing cellulose ethers)
IT 3812-32-6, Carbonate ion, biological studies 7558-79-4, Dibasic sodium phosphate **9004-34-6D**, Cellulose, ethers, biological studies **9004-59-5**, Methylethyl cellulose **9004-62-0**, Hydroxyethyl cellulose **9004-67-5**, Methyl cellulose 10049-21-5, Monosodium phosphate monohydrate 12258-53-6 14265-44-2, Phosphate, biological studies 16887-00-6, Chloride ion, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thermally-gelling drug delivery vehicles containing cellulose ethers)
IT **9004-34-6D**, Cellulose, ethers, biological studies **9004-59-5****
*** , Methylethyl cellulose ***9004-62-0**, Hydroxyethyl cellulose **9004-67-5**, Methyl cellulose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thermally-gelling drug delivery vehicles containing cellulose ethers)
RN 9004-34-6 HCAPLUS
CN Cellulose (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9004-59-5 HCAPLUS
CN Cellulose, ethyl methyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

H_3C-OH

CM 3

CRN 64-17-5
CMF C2 H6 O

H_3C-CH_2-OH

RN 9004-62-0 HCAPLUS
CN Cellulose, 2-hydroxyethyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 107-21-1
CMF C2 H6 O2

HO—CH_2—CH_2—OH

RN 9004-67-5 HCAPLUS
CN Cellulose, methyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

H_3C—OH

L116 ANSWER 25 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:350257 HCAPLUS
DN 125:19002
ED Entered STN: 18 Jun 1996
TI Thermally-gelling **ophthalmic** drug delivery vehicles containing cellulose ethers
IN Kabra, Bhagwati P.; Lang, John C.
PA Alcon Laboratories, Inc., USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-00
ICS A61K047-38
CC 63-5 (Pharmaceuticals)
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9606597	A1	19960307	WO 1995-US10877	19950823 <--
	W: AU, CA, CN, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2172373	AA	19960307	CA 1995-2172373	19950823 <--
	CA 2172373	C	19990316		
	AU 9534965	A1	19960322	AU 1995-34965	19950823 <--
	AU 686455	B2	19980205		
	EP 725628	A1	19960814	EP 1995-931603	19950823 <--
	EP 725628	B1	20011107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1134662	A	19961030	CN 1995-190826	19950823 <--
	JP 09508143	T2	19970819	JP 1995-508897	19950823 <--
	AT 208186	E	20011115	AT 1995-931603	19950823 <--
	ES 2162638	T3	20020101	ES 1995-931603	19950823 <--
	PT 725628	T	20020328	PT 1995-931603	19950823 <--
	TW 460288	B	20011021	TW 1995-84108938	19950828 <--
	HK 1012558	A1	20020222	HK 1998-113839	19981217 <--
PRAI	US 1994-298244	A	19940830 <--		
	WO 1995-US10877	W	19950823 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9606597	ICM	A61K009-00
	ICS	A61K047-38
WO 9606597	ECLA	A61K009/00M16; A61K047/38 <--

AB Drug delivery vehicles which reversibly increase in either loss modulus or storage modulus, or both, upon contact with the **eye**, skin, mucous membrane of body cavity are disclosed. The vehicles contain one or more nonionic substituted cellulose ethers and do not require a charged surfactant or a pH-sensitive polymer for such increase in loss modulus or storage modulus, or both, upon administration. In one embodiment, the vehicles gel upon instillation in the **eye.** A solution of 3% methylethyl cellulose was stirred in ice bath for 2 h to completely hydrate the polymer, then the solution was left at room temperature; the osmolality of this solution was .apprx.13 mOsm. The **viscoelastic** properties of the solution was measured at 25° for 30 min followed by a ramp from 25-35° at a rate of 1°/min and followed by an isotherm at 35° for 60 min. by dynamic mech. thermal analyzer. The storage modulus of this sample increased by more than 50 Pa by raising the temperature from 25 to 35°.

ST gelling **ophthalmic** drug vehicle cellulose ether

IT **Glaucoma (disease)**
(inhibitors; thermally-gelling **ophthalmic** drug delivery vehicles containing cellulose ethers)

IT Allergy inhibitors
Anion exchangers
Anti-infective agents
Antihypertensives
Cation exchangers
Gelation
Immunosuppressants
Inflammation inhibitors
(thermally-gelling **ophthalmic** drug delivery vehicles containing cellulose ethers)

IT Animal growth regulators
Prostaglandins
Proteins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thermally-gelling **ophthalmic** drug delivery vehicles containing cellulose ethers)

IT Neurotransmitter agonists
(dopaminergic, thermally-gelling **ophthalmic** drug delivery vehicles containing cellulose ethers)

IT Pharmaceutical dosage forms
(**ophthalmic**, thermally-gelling **ophthalmic** drug delivery vehicles containing cellulose ethers)

IT **9004-58-4**, Ethylhydroxyethyl cellulose **9004-59-5**, Methylethyl cellulose
RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(thermally-gelling **ophthalmic** drug delivery vehicles containing cellulose ethers)

IT 75345-27-6, Polyquad
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(thermally-gelling **ophthalmic** drug delivery vehicles containing cellulose ethers)

IT **9004-34-6D**, Cellulose, ethers
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thermally-gelling **ophthalmic** drug delivery vehicles containing cellulose ethers)

IT **9004-58-4**, Ethylhydroxyethyl cellulose **9004-59-5**,
Methylethyl cellulose
RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(thermally-gelling **ophthalmic** drug delivery vehicles containing cellulose ethers)

RN 9004-58-4 HCAPLUS
CN Cellulose, ethyl 2-hydroxyethyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 107-21-1
CMF C2 H6 O2



CM 3

CRN 64-17-5
CMF C2 H6 O



RN 9004-59-5 HCAPLUS
CN Cellulose, ethyl methyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 64-17-5
CMF C2 H6 O

H_3C-CH_2-OH

IT **9004-34-6D**, Cellulose, ethers
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thermally-gelling **ophthalmic** drug delivery vehicles containing cellulose ethers)
RN 9004-34-6 HCAPLUS
CN Cellulose (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L116 ANSWER 26 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:528646 HCAPLUS
DN 122:274071
ED Entered STN: 06 May 1995
TI Bioadhesive emulsions for enhanced drug delivery
IN Friedman, Doron; Schwarz, Joseph; Amselem, Shimon
PA Pharmos Corp., USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-107
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9505163	A1	19950223	WO 1994-US8803	19940805 <--
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5744155	A	19980428	US 1993-106262	19930813 <--
	CA 2169357	AA	19950223	CA 1994-2169357	19940805 <--
	AU 9474511	A1	19950314	AU 1994-74511	19940805 <--
	AU 692460	B2	19980611		
	EP 714289	A1	19960605	EP 1994-924125	19940805 <--
	R: AT, BE, CH, DE, FR, GB, IE, IT, LI, LU				
	IL 110588	A1	20000601	IL 1994-110588	19940808 <--
	US 5993846	A	19991130	US 1998-63660	19980421 <--
PRAI	US 1993-106262	A	19930813 <--		
	WO 1994-US8803	W	19940805 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9505163	ICM	A61K009-107
WO 9505163	ECLA	A61K009/00M16; A61K009/00M18D; A61K009/107D <--
US 5744155	ECLA	A61K009/00M18D; A61K009/00M16; A61K009/107D <--
US 5993846	ECLA	A61K009/00M18D; A61K009/00M16; A61K009/107D <--

AB Novel compns. are provided for administering drugs. to mucosal surface using bioadhesive emulsions of the "lipid-water" type containing suitable drugs. Thus, a solution of Carbopol-940 0.250 g and glycerol 11.2 g in 420 mL water was mixed with an oil phase consisting of pilocarpine 10.5, medium-chain triglycerides 21.2, Lipoid E-75 3.75, and Miranol MHT 7.8 g. The mixture was further mixed with 50 mg thiomersal and 1.0 g chlorobutanol in 50 mL water.
ST bioadhesive emulsion drug delivery; polymer surfactant bioadhesive emulsion; Carbopol 940 triglyceride bioadhesive emulsion
IT Steroids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anabolic; bioadhesive emulsions for enhanced drug delivery)

IT Adrenergic antagonists
Analgesics
Anesthetics
Antibiotics
Anticonvulsants and Antiepileptics
Antidepressants
Anxiolytics
Cholinergic agonists
Cryoprotectants
Drug bioavailability
Eye
Fungicides and Fungistats
Inflammation inhibitors
Miotics
Mucous membrane
Neoplasm inhibitors
Surfactants
Virucides and Virustats
(bioadhesive emulsions for enhanced drug delivery)

IT Amino acids, biological studies
Cardiolipins
Estrogens
Glycerides, biological studies
Glycosaminoglycans, biological studies
Hormones
Lysophosphatidylcholines
Paraffin oils
Phosphatidic acids
Phosphatidylcholines, biological studies
Phosphatidylethanolamines
Phosphatidylglycerols
Phosphatidylinositols
Phosphatidylserines
Phospholipids, biological studies
Polymers, biological studies
Prostaglandins
Siloxanes and Silicones, biological studies
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioadhesive emulsions for enhanced drug delivery)

IT **Prostaglandins**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(I, bioadhesive emulsions for enhanced drug delivery)

IT Lipoproteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apo-, bioadhesive emulsions for enhanced drug delivery)

IT Intestine
(colon, bioadhesive emulsions for enhanced drug delivery)

IT Lecithins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(egg yolk, bioadhesive emulsions for enhanced drug delivery)

IT Pharmaceutical dosage forms
(emulsions, bioadhesive emulsions for enhanced drug delivery)

IT Pharmaceutical dosage forms
(emulsions, topical, bioadhesive emulsions for enhanced drug delivery)

IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(esters, bioadhesive emulsions for enhanced drug delivery)

IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated, bioadhesive emulsions for enhanced drug delivery)

IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fatty, bioadhesive emulsions for enhanced drug delivery)
IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fatty, ethoxylated, bioadhesive emulsions for enhanced drug delivery)
IT Tranquilizers and Neuroleptics
(major, bioadhesive emulsions for enhanced drug delivery)
IT Glycerides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mono-, bioadhesive emulsions for enhanced drug delivery)
IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligo-, bioadhesive emulsions for enhanced drug delivery)
IT 52-53-9, Verapamil 53-86-1, Indomethacin 54-71-7, Pilocarpine hydrochloride 57-88-5, Cholesterol, biological studies **79-41-4D**, Methacrylic acid, derivs., polymers 92-13-7, Pilocarpine 151-21-3, Sodium dodecyl sulfate, biological studies 9000-36-6, Karaya gum 9000-65-1, Tragacanth gum 9000-69-5, Pectin **9003-01-4**, Poly(acrylic acid) 9003-39-8, PVP **9004-32-4** 9004-54-0, Dextran T-70, biological studies 9004-61-9, Hyaluronic acid 9004-99-3, Simulsol M53 9005-32-7, Alginic acid 9005-38-3, Sodium alginate 9005-49-6, Heparin, biological studies **9005-65-6**, Tween 80 9011-16-9, Maleic anhydride-methyl vinyl ether copolymer 9012-76-4, Chitosan 9041-08-1, Fragmin 15307-86-5, Diclofenac 25301-02-4, Tyloxapol 25322-68-3D, PEG, fatty esters or alkyl Ph ethers 71463-34-8, Miranol MHT 76050-42-5, Carbopol 940
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioadhesive emulsions for enhanced drug delivery)
IT **79-41-4D**, Methacrylic acid, derivs., polymers **9003-01-4**, Poly(acrylic acid) **9004-32-4** **9005-65-6**, Tween 80
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioadhesive emulsions for enhanced drug delivery)
RN 79-41-4 HCAPLUS
CN 2-Propenoic acid, 2-methyl- (9CI) (CA INDEX NAME)



RN 9003-01-4 HCAPLUS
CN 2-Propenoic acid, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 79-10-7
CMF C3 H4 O2



RN 9004-32-4 HCAPLUS
CN Cellulose, carboxymethyl ether, sodium salt (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
CMF C2 H4 O3



RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L116 ANSWER 27 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:610773 HCAPLUS
DN 119:210773
ED Entered STN: 13 Nov 1993
TI **Viscous ophthalmic pharmaceuticals** containing cellulosic polymers and carboxy vinyl polymers
IN Ali, Yusuf; Bhagat, Haresh G.
PA Alcon Laboratories, Inc., USA
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-08
ICS A61K047-38; A61K047-32
CC 63-6 (Pharmaceuticals)
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9317664	A1	19930916	WO 1993-US1565	19930222 <--
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9337287	A1	19931005	AU 1993-37287	19930222 <--
	US 5460834	A	19951024	US 1995-371043	19950110 <--
PRAI	US 1992-844269	A	19920302 <--		
	US 1991-807528	B1	19911213 <--		
	US 1992-994051	B2	19921216 <--		
	WO 1993-US1565	A	19930222 <--		
	US 1993-31058	B2	19930312 <--		
	US 1993-170482	B1	19931220 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9317664	ICM	A61K009-08
	ICS	A61K047-38; A61K047-32

AB **Viscous ophthalmic pharmaceuticals** contain a cellulosic polymer having an average mol. weight 10,000-13x106 0.05-5.0 and a carboxy vinyl polymer having an ave. mol. weight 500,000-6x106 0.05-3.0%. An **ophthalmic** composition containing HPMC 0.5, and Carbomer 934P 0.2% had **viscosity** of 6830 cP.
ST **ophthalmic** pharmaceutical carboxy vinyl polymer **viscosity**; cellulose deriv **ophthalmic** pharmaceutical **viscosity**; HPMC Carbomer 934P **ophthalmic** pharmaceutical **viscosity**
IT Adrenergic agonists

Allergy inhibitors
Anti-infective agents
Antihypertensives
Miotics
Prostaglandins
Retinoids
Steroids, biological studies
RL: BIOL (Biological study)
(**ophthalmic** pharmaceuticals containing cellulosic polymers and carboxy vinyl polymers and, **viscous**)

IT Neurotransmitter antagonists
(dopaminergic, **ophthalmic** pharmaceuticals containing cellulosic polymers and carboxy vinyl polymers and, **viscous**)

IT **Eye, disease**
(**keratoconjunctivitis sicca**, treatment of, with **ophthalmic** pharmaceuticals containing cellulosic polymers and carboxy vinyl polymers)

IT Pharmaceutical dosage forms
(**ophthalmic**, **viscous**, cellulosic polymers and carboxy vinyl polymers in)

IT Adrenergic antagonists
(β-, **ophthalmic** pharmaceuticals containing cellulosic polymers and carboxy vinyl polymers and, **viscous**)

IT 9000-81-1, Acetylcholinesterase 9001-03-0, Carbonic anhydrase 9028-31-3, Aldose reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, **ophthalmic** pharmaceuticals containing cellulosic polymers and carboxy vinyl polymers and, **viscous**)

IT **9004-62-0**, Hydroxyethyl cellulose **9004-64-2**, Hydroxypropyl cellulose **9004-65-3** **9004-67-5**, Methyl cellulose
RL: BIOL (Biological study)
(**ophthalmic** pharmaceuticals containing carboxy vinyl polymers and, **viscous**)

IT 50-02-2, Dexamethasone 51-43-4, Epinephrine 51-83-2, Carbachol 53-02-1, Tetrahydrocortisol **56-81-5**, 1,2,3-Propanetriol, biological studies **59-66-5**, Acetazolamide 92-13-7, Pilocarpine 452-35-7, Ethoxzolamide 554-57-4, Methazolamide 7733-02-0, Zinc sulfate **9002-89-5**, Poly(vinyl alcohol) 9003-39-8, PVP 9004-54-0, Dextran 70, biological studies 12441-09-7D, Sorbitan, derivs. 25322-68-3 26839-75-8, Timolol 40828-46-4, Suprofen 47141-42-4, Levobunolol 49697-38-3, Rimexolone 56298-24-9, Dipivalylepinephrine 63659-18-7, Betaxolol 66711-21-5 74103-06-3, Ketorolac 85721-33-1, Ciprofloxacin
RL: BIOL (Biological study)
(**ophthalmic** pharmaceuticals containing cellulosic polymers and carboxy vinyl polymers and, **viscous**)

IT 57916-92-4, Carbomer 934p 76050-42-5, Carbomer 940 91315-32-1, Carbomer 910 96827-24-6, Carbomer 1342
RL: BIOL (Biological study)
(**ophthalmic** pharmaceuticals containing cellulosic polymers and, **viscous**)

IT **9004-62-0**, Hydroxyethyl cellulose **9004-64-2**, Hydroxypropyl cellulose **9004-65-3** **9004-67-5**, Methyl cellulose
RL: BIOL (Biological study)
(**ophthalmic** pharmaceuticals containing carboxy vinyl polymers and, **viscous**)

RN 9004-62-0 HCAPLUS
CN Cellulose, 2-hydroxyethyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 107-21-1
CMF C2 H6 O2



RN 9004-64-2 HCAPLUS
CN Cellulose, 2-hydroxypropyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9004-65-3 HCAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9004-67-5 HCAPLUS
CN Cellulose, methyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



IT **56-81-5**, 1,2,3-Propanetriol, biological studies **59-66-5**, Acetazolamide **9002-89-5**, Poly(vinyl alcohol)
RL: BIOL (Biological study)
(**ophthalmic** pharmaceuticals containing cellulosic polymers and carboxy vinyl polymers and, **viscous**)
RN 56-81-5 HCAPLUS
CN 1,2,3-Propanetriol (9CI) (CA INDEX NAME)



RN 59-66-5 HCAPLUS
CN Acetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)



RN 9002-89-5 HCAPLUS
CN Ethenol, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 557-75-5
CMF C2 H4 O

$H_2C{=}CH{-}OH$

L116 ANSWER 28 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:221564 HCAPLUS
DN 116:221564
ED Entered STN: 31 May 1992
TI Treatment of **ocular** hypertension with 15-ketoprostaglandin derivative
IN **Ueno, Ryuji**
PA Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyusho, Japan
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM A61K031-557
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 26
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 458588	A1	19911127	EP 1991-304574	19910521 <--
EP 458588	B1	19941130		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2042972	AA	19911123	CA 1991-2042972	19910521 <--
CA 2042972	C	19961015		
US 5208256	A	19930504	US 1991-703660	19910521 <--
ES 2067864	T3	19950401	ES 1991-304574	19910521 <--
JP 04253910	A2	19920909	JP 1991-147792	19910522 <--
JP 07098751	B4	19951025		
PRAI JP 1990-132909		19900522 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 458588	ICM	A61K031-557

OS MARPAT 116:221564
AB Synergistic drugs for the treatment of **ocular** hypertension comprise a 13,14-dihydro-15-ketoprostaglandin derivative and an ethoxylated sorbitan unsatd. fatty acid monoester. **Eye** drops comprised 13,14-dihydro-15-keto-20-ethyl-PGF2α iso-Pr ester (I) 0.05, polysorbate-80 0.4, NaCl 0.8 g and water to 100 mL. The drugs (50 μL), applied to rabbit **eye**, decreased the **ocular** pressure, with only moderate side effects. The preparation of I is given.
ST **eye** antihypertensive prostaglandin sorbitan ester
IT **Glaucoma (disease)**
(treatment of, by synergistic compns. containing ketoprostaglandin derivative
and ethoxylated sorbitan esters)
IT 138829-60-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(Collins oxidation of)
IT 107-21-1, Ethylene glycol, biological studies
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization by, of oxodecylbicyclooctane derivative)
IT 75-30-9, Isopropyl iodide
RL: RCT (Reactant); RACT (Reactant or reagent)
(esterification by, of prostaglandin derivative)
IT 138665-26-6 141197-13-9
RL: BIOL (Biological study)
(**ocular** antihypertensive, synergistic)
IT **9005-65-6D**, mixts. with prostaglandin derivs. **138923-19-0D**, mixts. with ethoxylated sorbitan fatty acid monoesters

RL: BIOL (Biological study)
(**ocular** antihypertensives, synergistic)

IT **138829-67-1P** 138829-69-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and Jones oxidation of)

IT 138829-63-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of, with ethylene glycol)

IT 120373-42-4P
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and esterification of, with iso-Pr bromide)

IT 138829-62-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)

IT 138829-64-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

IT 120373-65-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of prostaglandin derivative as **ocular** antihypertensive)

IT 138829-61-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with di-Me oxononylphosphonate)

IT 138829-65-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with tert-butyldimethylsilyl chloride)

IT 138876-60-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

IT 138829-72-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ring opening of)

IT **138829-66-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tosylation of)

IT **138829-68-2P 138829-71-7P**
RL: PREP (Preparation)
(preparation of, as **ocular** antihypertensive agent)

IT 17814-85-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of **ocular** antihypertensive prostaglandin derivative)

IT 37497-25-9, Dimethyl (2-oxononyl)phosphonate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with bicyclooctane derivative)

IT 18162-48-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with prostaglandin derivative)

IT **9005-65-6D**, mixts. with prostaglandin derivs. **138923-19-0D**
, mixts. with ethoxylated sorbitan fatty acid monoesters
RL: BIOL (Biological study)
(**ocular** antihypertensives, synergistic)

RN 9005-65-6 HCAPLUS
CN Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs. (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 138923-19-0 HCAPLUS
CN 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, (5Z)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT **138829-67-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and Jones oxidation of)
RN 138829-67-1 HCAPLUS
CN 5-Heptenoic acid, 7-[5-hydroxy-3-[[(4-methylphenyl)sulfonyl]oxy]-2-(3-oxodecyl)cyclopentyl]-, 1,1-dimethylethyl ester, [1R-[1α(Z),2β,3α,5α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **138829-66-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tosylation of)
RN 138829-66-0 HCAPLUS
CN 5-Heptenoic acid, 7-[3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, 1,1-dimethylethyl ester, [1R-[1α(Z),2β,3α,5α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT **138829-68-2P 138829-71-7P**
RL: PREP (Preparation)
(preparation of, as **ocular** antihypertensive agent)
RN 138829-68-2 HCAPLUS
CN 5-Heptenoic acid, 7-[2-oxo-5-(3-oxodecyl)-3-cyclopenten-1-yl]-, 1,1-dimethylethyl ester, [1R-[1α(Z),5β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 138829-71-7 HCAPLUS
CN 5-Heptenoic acid, 7-[3-hydroxy-5-oxo-2-(3-oxodecyl)cyclopentyl]-, 1,1-dimethylethyl ester, [1R-[1α(Z),2β,3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L116 ANSWER 29 OF 29 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:191885 HCAPLUS
DN 112:191885
ED Entered STN: 26 May 1990
TI The effect of **viscoelastic** materials on rabbit blood-aqueous

barrier
AU Machi, Naoko
CS Sch. Med., Jikei Univ., Tokyo, Japan
SO Tokyo Jikeikai Ika Daigaku Zasshi (**1989**), 104(5), 885-91
CODEN: TJIDAH; ISSN: 0375-9172
DT Journal
LA Japanese
CC 1-12 (Pharmacology)
AB The effects of Na hyaluronate (I) and methy cellulose (II) on the protein and prostaglandin content in the anterior chamber of the yee were studied in rabbits. Samples of the aqueous humor were withdrawn 6, 12, and 48 h and 7 days after the injection of I and II. Six hours after injection, I had increased the protein level to .apprx.1.5 times that of controls, and II increased it 2.4 times more than I. The prostaglandin levels showed no consistent effect. It is suggested that II induced a greater breakdown of the blood-aqueous barrier than did I.
ST blood aq human barrier hyaluronate cellulose
IT **Prostaglandins**
Proteins, biological studies
RL: BIOL (Biological study)
(of **eye** aqueous humor, hyaluronate and Me cellulose effect on)
IT Blood
(-aqueous humor barrier, hyaluronate and Me cellulose effect on)
IT **Eye**
(aqueous humor, -blood barrier, hyaluronate and Me cellulose effect on)
IT 9004-61-9, Hyaluronic acid **9004-67-5**, Methyl cellulose
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(blood-aqueous humor barrier response to)
IT **9004-67-5**, Methyl cellulose
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(blood-aqueous humor barrier response to)
RN 9004-67-5 HCAPLUS
CN Cellulose, methyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

H_3C-OH

=>

false hit